NZ739942B2 - Chimeric cytokine receptor - Google Patents
Chimeric cytokine receptorInfo
- Publication number
- NZ739942B2 NZ739942B2 NZ739942A NZ73994216A NZ739942B2 NZ 739942 B2 NZ739942 B2 NZ 739942B2 NZ 739942 A NZ739942 A NZ 739942A NZ 73994216 A NZ73994216 A NZ 73994216A NZ 739942 B2 NZ739942 B2 NZ 739942B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- nucleic acid
- cell
- receptor
- cells
- acid sequence
- Prior art date
Links
- 102000003675 cytokine receptors Human genes 0.000 title claims description 207
- 108010057085 cytokine receptors Proteins 0.000 title claims description 207
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 70
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 54
- 229920001184 polypeptide Polymers 0.000 claims abstract description 52
- 108091005703 transmembrane proteins Proteins 0.000 claims abstract description 37
- 102000035160 transmembrane proteins Human genes 0.000 claims abstract description 36
- 210000004027 cell Anatomy 0.000 claims description 190
- 150000007523 nucleic acids Chemical group 0.000 claims description 139
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 106
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 94
- 239000000427 antigen Substances 0.000 claims description 78
- 102000036639 antigens Human genes 0.000 claims description 77
- 108091007433 antigens Proteins 0.000 claims description 77
- 239000003446 ligand Substances 0.000 claims description 70
- 239000013598 vector Substances 0.000 claims description 51
- 102000039446 nucleic acids Human genes 0.000 claims description 45
- 108020004707 nucleic acids Proteins 0.000 claims description 45
- 108010002350 Interleukin-2 Proteins 0.000 claims description 40
- 102000000588 Interleukin-2 Human genes 0.000 claims description 40
- 125000006850 spacer group Chemical group 0.000 claims description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 37
- 201000010099 disease Diseases 0.000 claims description 36
- 102000005962 receptors Human genes 0.000 claims description 33
- 108020003175 receptors Proteins 0.000 claims description 33
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 claims description 27
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 18
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 18
- 101710160107 Outer membrane protein A Proteins 0.000 claims description 15
- 102000010782 Interleukin-7 Receptors Human genes 0.000 claims description 14
- 108010038498 Interleukin-7 Receptors Proteins 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 9
- 230000004186 co-expression Effects 0.000 claims description 9
- 210000002865 immune cell Anatomy 0.000 claims description 7
- 230000001461 cytolytic effect Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 102000004556 Interleukin-15 Receptors Human genes 0.000 claims description 5
- 108010017535 Interleukin-15 Receptors Proteins 0.000 claims description 5
- 210000000170 cell membrane Anatomy 0.000 claims description 5
- 108010002082 endometriosis protein-1 Proteins 0.000 claims description 5
- 230000001177 retroviral effect Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 4
- 108020004705 Codon Proteins 0.000 claims description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 3
- 239000003623 enhancer Substances 0.000 claims description 2
- 230000006801 homologous recombination Effects 0.000 claims description 2
- 238000002744 homologous recombination Methods 0.000 claims description 2
- 241001446467 Mama Species 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000004308 thiabendazole Substances 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 abstract description 31
- 108090000695 Cytokines Proteins 0.000 abstract description 31
- 230000011664 signaling Effects 0.000 abstract description 25
- 102000042286 type I cytokine receptor family Human genes 0.000 abstract description 12
- 108091052247 type I cytokine receptor family Proteins 0.000 abstract description 12
- 230000027455 binding Effects 0.000 description 79
- 210000001744 T-lymphocyte Anatomy 0.000 description 72
- 206010028980 Neoplasm Diseases 0.000 description 68
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 57
- 102100038358 Prostate-specific antigen Human genes 0.000 description 57
- 102000019034 Chemokines Human genes 0.000 description 36
- 108010012236 Chemokines Proteins 0.000 description 36
- 238000006471 dimerization reaction Methods 0.000 description 34
- 210000000822 natural killer cell Anatomy 0.000 description 26
- 201000011510 cancer Diseases 0.000 description 25
- 238000003776 cleavage reaction Methods 0.000 description 24
- 230000007017 scission Effects 0.000 description 24
- 150000001413 amino acids Chemical group 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 20
- 108010076504 Protein Sorting Signals Proteins 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 19
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 17
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 16
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 16
- 206010060862 Prostate cancer Diseases 0.000 description 15
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 15
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 15
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 15
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 14
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 14
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 12
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 150000002500 ions Chemical class 0.000 description 12
- 210000003289 regulatory T cell Anatomy 0.000 description 12
- 102100023123 Mucin-16 Human genes 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 10
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 10
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 10
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 10
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 10
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 102000001902 CC Chemokines Human genes 0.000 description 9
- 108010040471 CC Chemokines Proteins 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 239000011230 binding agent Substances 0.000 description 9
- 235000018417 cysteine Nutrition 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 210000003071 memory t lymphocyte Anatomy 0.000 description 9
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 8
- 102000003812 Interleukin-15 Human genes 0.000 description 8
- 108090000172 Interleukin-15 Proteins 0.000 description 8
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 8
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 8
- 210000002307 prostate Anatomy 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 108700013048 CCL2 Proteins 0.000 description 7
- 101710120463 Prostate stem cell antigen Proteins 0.000 description 7
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 6
- 108050006947 CXC Chemokine Proteins 0.000 description 6
- 102000019388 CXC chemokine Human genes 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 6
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 6
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 6
- 241001529936 Murinae Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 6
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 5
- 102000009410 Chemokine receptor Human genes 0.000 description 5
- 108050000299 Chemokine receptor Proteins 0.000 description 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 5
- 102000004961 Furin Human genes 0.000 description 5
- 108090001126 Furin Proteins 0.000 description 5
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 108010002586 Interleukin-7 Proteins 0.000 description 5
- 102100021592 Interleukin-7 Human genes 0.000 description 5
- 108091008874 T cell receptors Proteins 0.000 description 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 5
- 241000723792 Tobacco etch virus Species 0.000 description 5
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 5
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000001794 hormone therapy Methods 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 230000004068 intracellular signaling Effects 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 102000042838 JAK family Human genes 0.000 description 4
- 108091082332 JAK family Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 108010022394 Threonine synthase Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 108010082017 alpha chain interleukin-7 receptor Proteins 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 102000004419 dihydrofolate reductase Human genes 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 3
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 3
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 3
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 3
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 3
- 108010008629 CA-125 Antigen Proteins 0.000 description 3
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 3
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 3
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 3
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 3
- 108010065524 CD52 Antigen Proteins 0.000 description 3
- 241000710190 Cardiovirus Species 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 3
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000002975 chemoattractant Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 235000019833 protease Nutrition 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229960002930 sirolimus Drugs 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 108010087967 type I signal peptidase Proteins 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 108091008875 B cell receptors Proteins 0.000 description 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 108050005711 C Chemokine Proteins 0.000 description 2
- 102000017483 C chemokine Human genes 0.000 description 2
- 102000007269 CA-125 Antigen Human genes 0.000 description 2
- 102100024263 CD160 antigen Human genes 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 101100063432 Caenorhabditis elegans dim-1 gene Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010055166 Chemokine CCL5 Proteins 0.000 description 2
- 102000010792 Chromogranin A Human genes 0.000 description 2
- 108010038447 Chromogranin A Proteins 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 102100035298 Cytokine SCM-1 beta Human genes 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 241000214054 Equine rhinitis A virus Species 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 2
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 description 2
- 101000804771 Homo sapiens Cytokine SCM-1 beta Proteins 0.000 description 2
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 2
- 108010002335 Interleukin-9 Proteins 0.000 description 2
- 102000000585 Interleukin-9 Human genes 0.000 description 2
- 108010024121 Janus Kinases Proteins 0.000 description 2
- 102000015617 Janus Kinases Human genes 0.000 description 2
- 102000001399 Kallikrein Human genes 0.000 description 2
- 108060005987 Kallikrein Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 102100035304 Lymphotactin Human genes 0.000 description 2
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 101100112779 Mus musculus Cd247 gene Proteins 0.000 description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 2
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 2
- 108010082093 Placenta Growth Factor Proteins 0.000 description 2
- 102100035194 Placenta growth factor Human genes 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 2
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 2
- 108010076039 Polyproteins Proteins 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 102000014400 SH2 domains Human genes 0.000 description 2
- 108050003452 SH2 domains Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 2
- 108010076818 TEV protease Proteins 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- 241001648840 Thosea asigna virus Species 0.000 description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
- 101710112793 Tyrosine-protein kinase JAK1 Proteins 0.000 description 2
- 101710112792 Tyrosine-protein kinase JAK3 Proteins 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical group C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 108091008039 hormone receptors Proteins 0.000 description 2
- 210000002602 induced regulatory T cell Anatomy 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000003998 progesterone receptors Human genes 0.000 description 2
- 108090000468 progesterone receptors Proteins 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 102000027257 transmembrane receptors Human genes 0.000 description 2
- 108091008578 transmembrane receptors Proteins 0.000 description 2
- PZYFJWVGRGEWGO-UHFFFAOYSA-N trisodium;hydrogen peroxide;trioxido(oxo)vanadium Chemical compound [Na+].[Na+].[Na+].OO.OO.OO.[O-][V]([O-])([O-])=O PZYFJWVGRGEWGO-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000004862 vasculogenesis Effects 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- GXMBHQRROXQUJS-UHFFFAOYSA-N (2-hept-2-ynylsulfanylphenyl) acetate Chemical compound CCCCC#CCSC1=CC=CC=C1OC(C)=O GXMBHQRROXQUJS-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 1
- 101150023956 ALK gene Proteins 0.000 description 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 102000002226 Alkyl and Aryl Transferases Human genes 0.000 description 1
- 108010014722 Alkyl and Aryl Transferases Proteins 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102100022716 Atypical chemokine receptor 3 Human genes 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100023703 C-C motif chemokine 15 Human genes 0.000 description 1
- 102100036846 C-C motif chemokine 21 Human genes 0.000 description 1
- 102100036850 C-C motif chemokine 23 Human genes 0.000 description 1
- 102100021942 C-C motif chemokine 28 Human genes 0.000 description 1
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101150011672 CCL9 gene Proteins 0.000 description 1
- 108010062802 CD66 antigens Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 102000039968 CEA family Human genes 0.000 description 1
- 108091069214 CEA family Proteins 0.000 description 1
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 description 1
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 1
- 102100035445 Carcinoembryonic antigen-related cell adhesion molecule 16 Human genes 0.000 description 1
- 102100035440 Carcinoembryonic antigen-related cell adhesion molecule 18 Human genes 0.000 description 1
- 102100035439 Carcinoembryonic antigen-related cell adhesion molecule 19 Human genes 0.000 description 1
- 102100024530 Carcinoembryonic antigen-related cell adhesion molecule 20 Human genes 0.000 description 1
- 102100024531 Carcinoembryonic antigen-related cell adhesion molecule 21 Human genes 0.000 description 1
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 description 1
- 102100025472 Carcinoembryonic antigen-related cell adhesion molecule 4 Human genes 0.000 description 1
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 description 1
- 102100025474 Carcinoembryonic antigen-related cell adhesion molecule 7 Human genes 0.000 description 1
- 102100025470 Carcinoembryonic antigen-related cell adhesion molecule 8 Human genes 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 102000006433 Chemokine CCL22 Human genes 0.000 description 1
- 108010083701 Chemokine CCL22 Proteins 0.000 description 1
- 102000001326 Chemokine CCL4 Human genes 0.000 description 1
- 108010055165 Chemokine CCL4 Proteins 0.000 description 1
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 1
- 102100035294 Chemokine XC receptor 1 Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108090000227 Chymases Proteins 0.000 description 1
- 102000003858 Chymases Human genes 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 206010055114 Colon cancer metastatic Diseases 0.000 description 1
- 108010003384 Colony-Stimulating Factor Receptors Proteins 0.000 description 1
- 102000004626 Colony-Stimulating Factor Receptors Human genes 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 206010071975 EGFR gene mutation Diseases 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 101150027879 FOXP3 gene Proteins 0.000 description 1
- 201000001342 Fallopian tube cancer Diseases 0.000 description 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
- 102000004641 Fetal Proteins Human genes 0.000 description 1
- 108010003471 Fetal Proteins Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 1
- 102000013818 Fractalkine Human genes 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- ZZLWLWSUIBSMNP-CIUDSAMLSA-N His-Asp-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O ZZLWLWSUIBSMNP-CIUDSAMLSA-N 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 1
- 101000678890 Homo sapiens Atypical chemokine receptor 3 Proteins 0.000 description 1
- 101000978376 Homo sapiens C-C motif chemokine 15 Proteins 0.000 description 1
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 1
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 description 1
- 101000897477 Homo sapiens C-C motif chemokine 28 Proteins 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 1
- 101000737645 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 16 Proteins 0.000 description 1
- 101000737663 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 18 Proteins 0.000 description 1
- 101000737655 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 19 Proteins 0.000 description 1
- 101000981108 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 20 Proteins 0.000 description 1
- 101000981110 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 21 Proteins 0.000 description 1
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 description 1
- 101000914325 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 4 Proteins 0.000 description 1
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101000914320 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 8 Proteins 0.000 description 1
- 101000804783 Homo sapiens Chemokine XC receptor 1 Proteins 0.000 description 1
- 101000856199 Homo sapiens Chymotrypsin-like protease CTRL-1 Proteins 0.000 description 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001003140 Homo sapiens Interleukin-15 receptor subunit alpha Proteins 0.000 description 1
- 101000605528 Homo sapiens Kallikrein-2 Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 101000773151 Homo sapiens Thioredoxin-like protein 4B Proteins 0.000 description 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- 101100273566 Humulus lupulus CCL10 gene Proteins 0.000 description 1
- -1 IL- 7 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 102000004559 Interleukin-13 Receptors Human genes 0.000 description 1
- 108010017511 Interleukin-13 Receptors Proteins 0.000 description 1
- 108010053727 Interleukin-15 Receptor alpha Subunit Proteins 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 102000013264 Interleukin-23 Human genes 0.000 description 1
- 108010066979 Interleukin-27 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
- 102000010682 Interleukin-9 Receptors Human genes 0.000 description 1
- 108010038414 Interleukin-9 Receptors Proteins 0.000 description 1
- 241001527806 Iti Species 0.000 description 1
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 1
- 102000008986 Janus Human genes 0.000 description 1
- 108050000950 Janus Proteins 0.000 description 1
- 101150003872 KLK3 gene Proteins 0.000 description 1
- 102100038356 Kallikrein-2 Human genes 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 101150105104 Kras gene Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 102000011716 Matrix Metalloproteinase 14 Human genes 0.000 description 1
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 102100031789 Myeloid-derived growth factor Human genes 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 108070000018 Neuropeptide receptor Proteins 0.000 description 1
- 102000028517 Neuropeptide receptor Human genes 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 102100036961 Nuclear mitotic apparatus protein 1 Human genes 0.000 description 1
- KRWMERLEINMZFT-UHFFFAOYSA-N O6-benzylguanine Chemical class C=12NC=NC2=NC(N)=NC=1OCC1=CC=CC=C1 KRWMERLEINMZFT-UHFFFAOYSA-N 0.000 description 1
- 229960005524 O6-benzylguanine Drugs 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010039918 Polylysine Chemical group 0.000 description 1
- 102000007584 Prealbumin Human genes 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- 108010002519 Prolactin Receptors Proteins 0.000 description 1
- 102100029000 Prolactin receptor Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000006437 Proprotein Convertases Human genes 0.000 description 1
- 108010044159 Proprotein Convertases Proteins 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101800001065 Protein 2B Proteins 0.000 description 1
- 101150002757 RSL1 gene Proteins 0.000 description 1
- 101001039269 Rattus norvegicus Glycine N-methyltransferase Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- 108010047827 Sialic Acid Binding Immunoglobulin-like Lectins Proteins 0.000 description 1
- 102000007073 Sialic Acid Binding Immunoglobulin-like Lectins Human genes 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 102100030273 Thioredoxin-like protein 4B Human genes 0.000 description 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 1
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 1
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 1
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 1
- 102100035071 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 1
- 229960000853 abiraterone Drugs 0.000 description 1
- SAZUGELZHZOXHB-UHFFFAOYSA-N acecarbromal Chemical compound CCC(Br)(CC)C(=O)NC(=O)NC(C)=O SAZUGELZHZOXHB-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 208000037842 advanced-stage tumor Diseases 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 1
- 229960001573 cabazitaxel Drugs 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000001360 collision-induced dissociation Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960004671 enzalutamide Drugs 0.000 description 1
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 101150034785 gamma gene Proteins 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000006195 histone acetylation Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000003297 immature b lymphocyte Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 210000004964 innate lymphoid cell Anatomy 0.000 description 1
- 229950004101 inotuzumab ozogamicin Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 108090000681 interleukin 20 Proteins 0.000 description 1
- 102000004114 interleukin 20 Human genes 0.000 description 1
- 102000002467 interleukin receptors Human genes 0.000 description 1
- 108010093036 interleukin receptors Proteins 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 description 1
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 108010074109 interleukin-22 Proteins 0.000 description 1
- 108040006861 interleukin-7 receptor activity proteins Proteins 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940076783 lucentis Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- QYYXITIZXRMPSZ-UHFFFAOYSA-N n'-tert-butyl-n'-(3,5-dimethylbenzoyl)-2-ethyl-3-methoxybenzohydrazide Chemical compound CCC1=C(OC)C=CC=C1C(=O)NN(C(C)(C)C)C(=O)C1=CC(C)=CC(C)=C1 QYYXITIZXRMPSZ-UHFFFAOYSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 108010036112 nuclear matrix protein 22 Proteins 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920000656 polylysine Chemical group 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940034080 provenge Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 108090000064 retinoic acid receptors Proteins 0.000 description 1
- 102000003702 retinoic acid receptors Human genes 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 229960000714 sipuleucel-t Drugs 0.000 description 1
- KISFEBPWFCGRGN-UHFFFAOYSA-M sodium;2-(2,4-dichlorophenoxy)ethyl sulfate Chemical compound [Na+].[O-]S(=O)(=O)OCCOC1=CC=C(Cl)C=C1Cl KISFEBPWFCGRGN-UHFFFAOYSA-M 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229940022511 therapeutic cancer vaccine Drugs 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 102000042287 type II cytokine receptor family Human genes 0.000 description 1
- 108091052254 type II cytokine receptor family Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001135—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
Abstract
The present invention provides a chimeric transmembrane protein which comprises two polypeptides: a first polypeptide which comprises a heavy chain constant domain (CH) and a first chain of a type I cytokine receptor endodomain; and a second polypeptide which comprises a light chain constant domain (CL) a second chain of the type I cytokine-receptor endodomain. The CH and CL domains spontaneously heterodimerise giving constitutively active type I cytokine signalling. (CL) a second chain of the type I cytokine-receptor endodomain. The CH and CL domains spontaneously heterodimerise giving constitutively active type I cytokine signalling.
Description
P108038PCT CHIMERIC CYTOKINE RECEPTOR FIELD OF THE INVENTION The present invention relates to a chimeric cytokine receptor (CCR), and a cell which expresses such a chimeric cytokine receptor and optionally a chimeric antigen receptor at the cell surface.
OUND TO THE INVENTION Chimeric antigen receptors (CARs) A number of immunotherapeutic agents have been described for use in cancer treatment, including therapeutic monoclonal antibodies , bi-specific T-cell engagers and chimeric antigen ors (CARs).
Chimeric antigen receptors are proteins which graft the specificity of a monoclonal dy (mAb) to the effector function of a T-cell. Their usual form is that of a type I transmembrane domain protein with an antigen recognizing amino terminus, a spacer, a transmembrane domain all connected to a compound endodomain which transmits T-cell survival and activation signals.
The most common form of these molecules are fusions of single-chain variable fragments (scFv) derived from monoclonal antibodies which ize a target antigen, fused via a spacer and a trans-membrane domain to a signaling endodomain. Such molecules result in activation of the T-cell in response to recognition by the scFv of its target. When T cells express such a CAR, they recognize and kill target cells that express the target antigen. Several CARs have been developed against tumour associated ns, and adoptive transfer approaches using such CAR-expressing T cells are currently in clinical trial for the treatment of various cancers.
CAR-based approaches to treat Prostate Cancer Prostate cancer is the second most common cancer in men worldwide, and the sixth g cause of cancer-related death. Globally, there are approximately 1,100,000 new cases and 300,000 ities every year, sing 4 percent of all cancer P108038PCT . It is estimated that 1 in every 6 men will be diagnosed with the disease during his lifetime.
Initial treatment for prostate cancer may consist of surgery, radiation, or hormone therapy, or any combination of each. Hormone therapy consists of lowering the levels of terone, the male hormone that fuels out-of-control cell growth. Chemotherapy is typically reserved for advanced-stage cancers.
When prostate cancers grow e the lowering of terone levels by hormone therapy, ent options are limited. Typically, the cancer e sipuleucel-T (Provenge®) a dendritic cell-based therapeutic cancer vaccine designed to induce an immune response targeted against the prostatic acid phosphatase ((PAP) antigen), a radiopharmaceutical agent (such as -223 chloride), secondary hormone therapies (such as abiraterone or enzalutamide), and/or chemotherapies (docetaxel and cabazitaxel) are added to the hormonal therapy in sequence. While each of these treatments can delay growth of the cancer for several months and palliate symptoms produced by the disease, the disease tely becomes resistant to them.
Preclinically, two antigens associated with prostate cancer have been targeted with CAR T-cell based therapies: prostate-specific membrane antigen (PSMA) and prostate stem cell n (PSCA).
Mice treated with PSCA CAR-engineered T cells showed delayed tumour growth (Hillerdal et al (2014) BMC Cancer 14:30; and Abate-Daga et al (2014) 25:1003-1012). gh the cells showed high in vitro cytotoxicity, in vivo, tumour growth was delayed but tumour-bearing mice were not cured.
This may be because, in vivo, CAR T-cells struggle to overcome the hostile microenvironment of a carcinoma. In particular CAR T-cells may fail to engraft and expand within a prostate cancer tumour bed.
CAR T-cell persistence and ty can be enhanced by administration of cytokines, or by the CAR T-cells producing cytokines constitutively. However, these approaches have limitations: systemic stration of cytokines can be toxic; constitutive production of cytokines may lead to uncontrolled proliferation and transformation (Nagarkatti et al (1994) PNAS 8-7642; Hassuneh et al (1997) Blood 89:610- 620).
There is therefore a need for alternative CAR T-cell approaches, which facilitate engraftment and expansion of T cells to counteract the effects of the hostile tumour microenvironment.
On-target off-tumour toxicity It is relatively rare for the presence of a single antigen effectively to describe a cancer, which can lead to a lack of specificity.
Most s cannot be differentiated from normal tissues on the basis of a single antigen. Hence, considerable "on-target mour" toxicity occurs whereby normal tissues are damaged by the y. For instance, whilst targeting CD20 to treat B-cell lymphomas with Rituximab, the entire normal B-cell compartment is depleted, whilst targeting CD52 to treat chronic lymphocytic leukaemia, the entire lymphoid tment is depleted, whilst targeting CD33 to treat acute myeloid leukaemia, the entire myeloid compartment is damaged etc.
The predicted problem of rgetoff-tumour" toxicity has been borne out by clinical trials. For example, an approach targeting ERBB2 caused death to a patient with colon cancer metastatic to the lungs and liver. ERBB2 is over-expressed in colon cancer in some ts, but it is also expressed on several normal s, ing heart and normal vasculature.
There is therefore a need for improved approaches to cancer therapy in which such "ontarget off-tumour" toxicity is d or eliminated.
DESCRIPTION OF THE FIGURES Figure 1: Schematic diagram summarising the structure of various cytokine receptors, the cell types which produce the cytokines and the cell types which express the cytokine receptors.
Figure 2: Schematic diagram showing proposed chimeric cytokine receptor (a) Cytokine IL2 and IL7 cytokine receptors signal through a common gamma chain and a cytokine specific alpha/beta chain.
P108038PCT (b) One entation of a chimeric cytokine receptor is to replace the ectodomain of the cytokine beta and gamma chain with different scFvs (or any other suitable binder) which recognize different epitopes of PSA. (c) An alternative approach is to e the ectodomains of alpha/beta and gamma with the VH / VL of a PSA specific antibody, where both VH and VL are involved in binding so that binding brings them together.
Figure 3: Aggregation-based cytokine signalling enhancer Schematic diagram showing a chimeric cytokine receptor and CAR combination system. The cell comprises two chimeric ne receptors which bind different es on the same soluble . In the absence of e ligand (e.g. PSA) but the presence of the embrane antigen (e.g. PSMA) signalling occurs thought the CAR. In the presence of the e ligand, aggregation of the two chimeric cytokine receptors occurs, leading to cytokine-based signal enhancement.
Figure 4: Theoretical construct map for the chimeric ne receptor/CAR combination system illustrated in Figure 3.
Figure 5: Schematic diagram illustrating an example of a structure for the chimeric transmembrane n of the present ion. The chimeric transmembrane protein comprises a dimerization domain and a cytokine receptor endodomain. The embodiment shown has a "Fab" type architecture, as the dimerization domain comprises antibody-type heavy and light chain constant regions. Constant dimerization between these domains brings together the IL2 receptor common γ chain with either the IL-2 receptor β chain or the IL-7 receptor α chain, leading to constitutive cytokine signalling.
Figure 6: IL-2 signalling by the chimeric transmembrane protein.
Two chimeric transmembrane ns having the general structure shown in Figure 5 were tested for their ability to induce IL-2 signalling. One chimeric transmembrane protein comprised an IL2 receptor endodomain and the other comprised an IL-7 receptor endodomain. IL-2 signalling was tested using the murine cell line CTLL2 which is dependent on IL-2 signalling for growth. As a positive control, CTLL2 cells were cultured with 100 u/mL murine IL2. Cells expressing the chimeric transmembrane protein comprising the IL2 receptor endodomain (Fab_IL2endo) supported CTLL2 cell survival and growth, whereas cells expressing the chimeric transmembrane protein comprising the IL-7 receptor (Fab_IL7endo) did not.
P108038PCT Figure 7: Schematic diagram illustrating panel of PSA chimeric cytokine receptors A panel of chimeric cytokine receptors (CCRs) targeting PSA was developed using scFvs derived from two antibodies which bind to different PSA epitopes: 5D5A5 and 5D3D11.
Top-left panel: A CCR with an IL-2R endodomain having A5 on the chain with IL2R β chain and D11 on the chain with common γ chain; Top-right panel: A CCR with an IL7R endodomain having A5 on the chain with IL7R α chain and D11 on the chain with common γ chain; Bottom-left panel: A CCR with an IL-2R endodomain having D11 on the chain with IL2R β chain and A5 on the chain with common γ chain; and Bottom-right hand panel: A CCR with an IL-7R endodomain having D11 on the chain with IL7R α chain and A5 on the chain with common γ chain.
A negative control was also created for each CCR, in which the IL2Rγ chain was ed by a rigid .
Figure 8: IL2 signalling from cells expressing a PSA chimeric cytokine receptor in the presence of PSA – CTLL2 proliferation CTLL2 cells were transduced with constructs expressing some of the PSA chimeric ne receptors illustrated in Figure 7. Cells were cultured in the presence of absence of IL2 (positive control) and the presence of absence of 5ng/mL or 5μg/mL PSA. CTLL2 proliferation was ed after 3 and 7 days.
The anti-PSA chimeric cytokine receptor with an IL2R main supported CTLL2 cell proliferation in the absence of IL2 and the presence of PSA, but not the receptor having an IL7R endodomain or any of the CCRs comprising a rigid linker in the place of the common γ chain.
Figure 9: IL2 signalling from cells sing a PSA chimeric ne receptor in the presence of PSA – CTLL2 STAT5 phosphorylation CTLL2 cells were either left untransduced (WT); or transduced with a vector expressing a CCR against PSA (D11-CD8STK-IL2Rg_A5-Hinge-IL2Rb) or an equivalent construct having a rigid linker in the place of the common γ chain (D11-CD8STK-RL_A5-Hinge- IL2Rb). Cells were ted with either 500μM Pervanadate or 500ng/mL PSA for 1 or 4 hours. orylation of Y694 of STAT5 was then investigated using phosphoflow.
SUMMARY OF ASPECTS OF THE INVENTION P108038PCT The present inventors have developed "chimeric cytokine receptors" (CCR) which graft the binding specificity of a non-cytokine binding molecule on to the endodomain of a cytokine receptor. The co-expression of such a CCR with a ic antigen receptor (CAR) helps a CAR T-cell to engraft and expand in the hostile tumour microenvironment. The ement for the ligand for the CCR as well as the ligand for the CAR to be present add another layer of selectivity and helps prevent on-target offtumour toxicity.
For example, they have developed a cell which co-expresses a CAR with a chimeric cytokine receptor which detects PSA and transmits an IL2/15 or an IL7 signal to the CAR . In this way, the CAR T-cell is stimulated to proliferate selectively only in a prostate cancer microenvironment, and in the absence of PSA (i.e. after the patient is in remission), the cytokine stimulation is lost.
In a first aspect, the present invention provides a chimeric cytokine receptor (CCR) comprising: an exodomain which binds to a ligand ed from a tumour secreted , a chemokine and a cell-surface antigen; and a cytokine receptor endodomain.
In a first embodiment of the first aspect of the invention, the chimeric cytokine receptor comprises two ptides: (i) a first polypeptide which comprises: (a) a first antigen-binding domain which binds a first epitope of the ligand (b) a first chain of the cytokine receptor endodomain; and (ii) a second polypeptide which comprises: (a) a second n-binding domain which binds a second epitope of the ligand (b) a second chain of the cytokine-receptor endodomain. Figure 2b illustrates such an arrangement.
Each of the first and second n-binding domains may be, for example, single- chain le fragments (scFvs) or single domain binders.
In a second ment of the first aspect of the invention, the ic cytokine receptor which comprises two polypeptides: (i) a first polypeptide which comprises: (a) a heavy chain variable domain (VH) (b) a first chain of the cytokine receptor endodomain; and (ii) a second polypeptide which comprises: (a) a light chain le domain (VL) (b) a second chain of the cytokine-receptor endodomain.
Figure 2c illustrates such an arrangement.
The first and second chains for the cytokine or endodomains may be ent and may be selected from type I cytokine receptor endodomain α-, β-, and γ-chains.
Alternatively the first and second chains for the cytokine receptor endodomains may be the same and may be selected from type I cytokine receptor endodomain α-, β-, and s.
For example, the cytokine receptor endodomain may comprise: (i) IL-2 receptor β-chain endodomain (ii) IL-7 receptor α-chain endodomain; (iii) IL-15 receptor α-chain endodomain; or (iv) common γ-chain receptor endodomain.
The cytokine receptor endodomain may comprise (i), (ii) or (iii); and (iv).
The ligand may be a tumour secreted factor, for example a tumour secreted factor selected from: prostate-specific antigen (PSA), carcinoembryonic antigen (CEA), vascular endothelial growth factor (VEGF) and CA125.
The ligand may be a chemokine, for example a chemokine selected from chemokine selected from: CXCL12, CCL2, CCL4, CCL5 and CCL22.
The ligand may be a urface molecule, such as a transmembrane protein. The ligand may be, for example, CD22.
P108038PCT In a second aspect, the present invention provides a cell which ses a chimeric cytokine receptor according to the first aspect of the invention.
The cell may comprise a first chimeric cytokine receptor and a second chimeric cytokine receptor which bind different epitopes on the same .
The cell may comprise a first chimeric cytokine receptor which comprises a type I ne receptor endodomain α- or β-chain, and a second chimeric ne receptor which comprises a type I cytokine receptor main γ-chain, such that when the first chimeric cytokine or and the second cytokine receptor bind the ligand, ed ling through the α-/β-chain and γ-chain occurs.
The cell may also comprise a chimeric antigen receptor, for example a chimeric antigen receptor which binds a tumour-associated cell surface antigen.
The chimeric antigen receptor may bind a cell surface antigen associated with prostate cancer, such as prostate stem-cell antigen (PSCA) or te-specific membrane antigen (PSMA).
Where the CCR recognises a cell-surface antigen, the CCR and CAR may recognise cell-surface antigens which are co-expressed on the same target (e.g. tumour) cell. For example, for B-cell malignancies, the CAR may recognize a cell-surface n such as CD19 and the CCR may recognize a molecule which is co-expressed on the target cell surface, such CD22, thereby enhancing engraftment.
In a third aspect, the present invention provides a nucleic acid ce encoding a chimeric cytokine receptor (CCR) according to the first aspect of the invention.
In a fourth aspect the present invention provides a nucleic acid construct which comprises a first nucleic acid sequence ng a first CCR and a second nucleic acid sequence encoding a second CCR, the nucleic acid construct having the structure: AgB1-spacer1-TM1-endo1-coexpr-AbB2-spacer2-TM2-endo2 in which AgB1 is a nucleic acid sequence encoding the antigen-binding domain of the first CCR; P108038PCT spacer 1 is a nucleic acid sequence encoding the spacer of the first CCR; TM1 is a a nucleic acid sequence encoding the transmembrane domain of the first CCR; endo 1 is a nucleic acid sequence encoding the endodomain of the first CCR; coexpr is a nucleic acid sequence enabling co-expression of both CCRs AgB2 is a nucleic acid sequence encoding the antigen-binding domain of the second CCR; spacer 2 is a nucleic acid sequence ng the spacer of the second CCR; TM2 is a a nucleic acid sequence encoding the transmembrane domain of the second CCR; endo 2 is a nucleic acid sequence encoding the main of the second The nucleic acid construct may also encode a chimeric antigen receptor (CAR). In this ment, the nucleic acid construct may have the structure: (i) CCRAgB1-CCRspacer1-CCRTM1-CCRendo1-coexpr1-CCRAgB2- CCRspacer2-CCRTM2-CCRendo2-coexpr2-CARAgB-CARspacer-CARTMCARendo (ii) CCRAgB1-CCRspacer1-CCRTM1-CCRendo1-coexpr1-CARAgBCARspacer-CARTM-CARendo-coexpr2-CCRAgB2-CCRspacer2-CCRTM2- CCRendo2; or (iii) CARAgB-CARspacer-CARTM-CARendo-coexpr1-CCRAgB1- CCRspacer1-CCRTM1-CCRendo1-coexpr2-CCRAgB2-CCRspacer2-CCRTM2- CCRendo2; in which CCRAgB1 is a nucleic acid sequence encoding the antigen-binding domain of the first CCR; CCRspacer1 is a nucleic acid sequence encoding the spacer of the first CCR; CCRTM1 is a nucleic acid ce encoding the transmembrane domain of the first CCR; o1 is a nucleic acid ce encoding the endodomain of the first P108038PCT CCRAgB2 is a nucleic acid sequence encoding the antigen-binding domain of the second CCR; CCRspacer2 is a nucleic acid sequence encoding the spacer of the second CCRTM2 is a nucleic acid sequence encoding the transmembrane domain of the second CCR; CCRendo2 is a nucleic acid sequence encoding the main of the second Coexpr1 and coexpr2 are nucleic acid sequences enabling co-expression of the two flanking sequences; CARAgB is a c acid sequence encoding the antigen-binding domain of the CAR; CARspacer is a nucleic acid sequence encoding the spacer of the CAR; CARTM is a nucleic acid sequence encoding the transmembrane domain of the CAR; and CARendo is a nucleic acid sequence ng the endodomain of the CAR.
Any or all of the sequences coexpr, coexpr1, 2 may encode a sequence comprising a self-cleaving peptide.
Alternative codons may be used in regions of sequence ng the same or similar amino acid sequences, in order to avoid homologous recombination.
In a fifth , the present invention provides a vector comprising a nucleic acid construct according to the fourth aspect of the invention.
The vector may be, for example, a retroviral vector or a lentiviral vector or a transposon.
In a sixth aspect, the present invention es a kit which comprises: i) a vector sing a nucleic acid sequence encoding a first CCR ing to the first aspect of the invention; and ii) a vector comprising a nucleic acid sequence encoding a second CCR according to the second aspect of the invention.
The kit may also comprise a vector comprising a nucleic acid sequence encoding a chimeric antigen receptor.
P108038PCT The kit may comprise: i) a vector comprising a nucleic acid sequence encoding a CCR according to the first aspect of the invention; and ii) a vector comprising a nucleic acid sequence encoding a chimeric antigen or.
In a seventh aspect, the present invention provides a method for making a cell according to the second aspect of the invention, which comprises the step of introducing: a nucleic acid sequence according to the third aspect of the invention; a nucleic acid construct according to the fourth aspect of the invention; a vector according to the fifth aspect of the invention; or a kit of vectors according to the sixth aspect of the invention, into a cell.
The cell may be from a sample isolated from a subject.
In an eighth , there is provided a pharmaceutical ition comprising a plurality of cells according to the second aspect of the invention.
In a ninth , there is provided a method for treating and/or preventing a disease, which comprises the step of administering a pharmaceutical composition according to the eighth aspect of the invention to a subject.
The method may comprise the following steps: (i) isolation of a cell-containing sample from a subject; (ii) uction or transfection of the cells with: a c acid sequence according to the third aspect of the invention; a nucleic acid construct according to the fourth aspect of the invention; a vector according to the fifth aspect of the invention; or a kit of vectors according to the sixth aspect of the invention; and (iii) administering the cells from (ii) to a the subject.
The sample may be a T-cell containing sample.
The disease may be a cancer.
There is also provided a pharmaceutical composition according to the eighth aspect of the invention for use in treating and/or ting a disease.
P108038PCT There is also provided the use of a cell according to the second aspect of the invention in the manufacture of a medicament for treating and/or preventing a disease.
Further aspects of the invention are summarised in the following numbered paragraphs: 1. A chimeric transmembrane protein comprising: a dimerization domain; and a cytokine receptor endodomain. 2. A chimeric transmembrane protein according to paragraph 1, wherein the dimerization domain comprises the zation portion of a heavy chain constant domain (CH) and a light chain constant domain (CL). 3. A chimeric transmembrane protein ing to any ing paragraph, which comprises two polypeptides: (i) a first ptide which ses: (a) a first dimerisation domain; and (b) a first chain of the cytokine receptor endodomain; and (ii) a second polypeptide which comprises: (a) a second dimerization domain, which dimerises with the first dimerization domain; and (b) a second chain of the cytokine-receptor endodomain. 4. A chimeric transmembrane protein according to paragraph 3, wherein the first and second dimerization domains either dimerise neously, or in the presence of a chemical inducer of dimerization (CID).
. A chimeric transmembrane protein according to paragraph 2, 3 or 4 which ses two polypeptides: (i) a first polypeptide which comprises: (a) a heavy chain constant domain (CH) (b) a first chain of the cytokine or endodomain; and (ii) a second polypeptide which ses: (a) a light chain constant domain (CL) (b) a second chain of the cytokine-receptor endodomain.
P108038PCT 6. A chimeric transmembrane protein according to paragraph 5 wherein the first and second chains for the cytokine receptor endodomains are different and are selected from type I cytokine receptor endodomain α-, β-, and γ-chains. 7. A chimeric transmembrane protein according to aph 5 wherein the first and second chains for the cytokine receptor endodomains are the same and are selected from type I cytokine receptor endodomain α-, β-, and γ-chains. 8. A chimeric transmembrane protein according to any ing paragraph, wherein the ne or endodomain comprises: (i) IL-2 receptor β-chain endodomain (ii) IL-7 receptor α-chain endodomain; or (iii) IL-15 receptor α-chain endodomain; and/or (iv) common γ-chain receptor endodomain. 9. A chimeric transmembrane protein ing to paragraph 5, wherein the first polypeptide comprises a heavy chain variable domain (VH) and a heavy chain constant domain (CH); and the second polypeptide comprises a light chain variable domain (VL) and a light chain nt domain (CL).
. A chimeric transmembrane protein according to paragraph 9 which comprises a Fab exodomain. 11. A cell which comprises a chimeric transmembrane protein according to any preceding paragraph. 12. A cell according to aph 11, which also comprises a chimeric antigen receptor. 13. A cell according to paragraph 12, wherein the chimeric antigen receptor binds a -associated cell surface antigen. 14. A c acid sequence ng a chimeric transmembrane protein ing to any of paragraphs 1 to 10.
. A nucleic acid construct which comprises a first nucleic acid sequence encoding a first polypeptide as defined in paragraph 3 and a second nucleic acid P108038PCT sequence encoding a second polypeptide as defined in paragraph 3, the nucleic acid construct having the structure: Dim1 -TM1-endo1-coexpr-Dim2 -TM2-endo2 in which Dim1 is a nucleic acid sequence encoding the first dimerisation domain; TM1 is a a nucleic acid sequence encoding the transmembrane domain of the first polypeptide; endo 1 is a nucleic acid sequence encoding the endodomain of the first polypeptide; coexpr is a nucleic acid sequence ng co-expression of both CCRs Dim2 is a c acid sequence encoding the second dimerization domain; TM2 is a a nucleic acid sequence encoding the transmembrane domain of the second polypeptide; endo 2 is a nucleic acid sequence encoding the endodomain of the second ptide. 16. A nucleic acid construct according to paragraph 15 which also s a chimeric antigen receptor (CAR). 17. A nucleic acid construct according to paragraph 15 or 16, n coexpr encodes a sequence comprising a leaving peptide. 18. A nucleic acid uct according to any of paragraphs 15 to 17, wherein alternative codons are used in regions of sequence encoding the same or similar amino acid sequences, in order to avoid gous recombination. 19. A vector comprising a nucleic acid construct according to any of paragraphs 15 to 18.
. A retroviral vector or a lentiviral vector or a transposon according to paragraph 19. 21. A kit which comprises: i) a vector sing a nucleic acid sequence encoding a first polypeptide as defined in paragraph 3; and P108038PCT ii) a vector comprising a nucleic acid sequence encoding a second polypeptide as defined in paragraph 3. 22. A kit according to paragraph 21 which also comprises a vector sing a nucleic acid sequence encoding a chimeric antigen receptor. 23. A kit which comprises: i) a vector comprising a nucleic acid sequence encoding a chimeric embrane proetin as defined in any of paragraphs 1 to 10; and ii) a vector comprising a nucleic acid sequence encoding a chimeric antigen receptor. 24. A method for making a cell according to any of paragraphs 11 to 13, which comprises the step of introducing: a nucleic acid sequence according to paragraph 14; a nucleic acid construct according to any of paragraphs 15 to 18; a vector according to paragraph 19 or 20; or a kit of vectors according to any paragraphs 21 to 23, into a cell.
. A method ing to aph 24, n the cell is from a sample isolated from a subject. 26. A pharmaceutical composition comprising a plurality of cells according to any of aphs 11 to 13. 27. A method for treating and/or preventing a disease, which comprises the step of administering a pharmaceutical composition according to paragraph 26 to a subject. 28. A method according to claim 27, which comprises the ing steps: (i) isolation of a cell-containing sample from a t; (ii) transduction or transfection of the cells with: a nucleic acid sequence according to paragraph 14; a nucleic acid construct according to any of paragraphs 15 to 18; a vector according to paragraph 19 or 20; or a kit of vectors according to any paragraphs 21 to 23,; and (iii) administering the cells from (ii) to a the subject.
P108038PCT 29. A method according to paragraph 28, wherein the sample is a T-cell containing sample.
. A method according to paragraph 28 or 29, n the disease is a cancer. 31. A pharmaceutical composition according to paragraph 26 for use in treating and/or preventing a disease. 32. The use of a cell according to any of paragraphs 11 to 13 in the manufacture of a medicament for treating and/or preventing a disease.
DETAILED DESCRIPTION CHIMERIC CYTOKINE RECEPTOR (CCR) A chimeric cytokine receptor (CCR) is a le which comprises a cytokine receptor endodomain and a heterologous ligand-binding exodomain. The heterologous exodomain binds a ligand other than the cytokine for which the cytokine receptor from which the endodomain was derived is selective. In this way, it is possible to alter the ligand specificity of a cytokine receptor by grafting on a logous binding specificity.
A chimeric cytokine receptor comprises: (i) a ligand g ain; (ii) an optional spacer; (iii) a transmembrane domain; and (iv) a cytokine-receptor endodomain.
CYTOKINE RECEPTORS AND SIGNALLING Many cell ons are regulated by members of the cytokine receptor superfamily.
Signalling by these receptors depends upon their association with Janus s (JAKs), which couple ligand binding to ne orylation of signalling proteins recruited to the receptor complex. Among these are the signal transducers and activators of transcription (STATs), a family of transcription factors that contribute to the diversity of cytokine responses.
P108038PCT When the chimeric cytokine receptor of the invention binds its ligand, one or more of the following intracellular signaling pathways may be initiated: (i) the JAK-STAT pathway (ii) the MAP kinase pathway; and (iii) the Phosphoinositide 3-kinase (PI3K) pathway.
The JAK-STAT system consists of three main components: (1) a receptor (2) Janus kinase (JAK) and (3) Signal Transducer and Activator of Transcription .
JAKs, which have tyrosine kinase activity, bind to cell surface cytokine receptors. The binding of the ligand to the receptor triggers activation of JAKs. With increased kinase ty, they phosphorylate tyrosine residues on the or and create sites for interaction with proteins that contain phosphotyrosine-binding SH2 domains. STATs possessing SH2 s capable of binding these phosphotyrosine residues are recruited to the receptors, and are themselves tyrosine-phosphorylated by JAKs. These otyrosines then act as binding sites for SH2 domains of other STATs, mediating their dimerization. Different STATs form hetero- or homodimers. Activated STAT dimers accumulate in the cell nucleus and activate ription of their target genes.
CYTOKINE RECEPTOR ENDODOMAIN The chimeric cytokine receptor of the present invention comprises an endodomain which causes "cytokine-type" cell signalling (either alone or when in the presence of r chimeric cytokine receptor) when the exodomain binds its ligand.
The endodomain may be a cytokine receptor endodomain.
The endodomain may be derived from a type I cytokine receptor. Type I cytokine receptors share a common amino acid motif (WSXWS) in the extracellular portion nt to the cell membrane.
The endodomain may be derived from a type II cytokine receptor.Type II cytokine ors include those that bind type I and type II interferons, and those that bind members of the interleukin-10 family leukin-10, interleukin-20 and interleukin-22).
Type I cytokine receptors include: P108038PCT (i) Interleukin receptors, such as the receptors for IL-2, IL-3, IL-4, IL-5, IL-6, IL- 7, IL-9, IL-11, IL-12, IL13, IL-15, IL-21, IL-23 and IL-27; (ii) Colony stimulating factor receptors, such as the receptors for erythropoietin, GM-CSF, and G-CSF; and (iii) Hormone receptor/neuropeptide receptor, such as hormone receptor and prolactin receptor s of the type I cytokine receptor family comprise different chains, some of which are involved in /cytokine interaction and others that are involved in signal uction. For example the IL-2 receptor comprises an α-chain, a β-chain and a γchain.
The IL-2 receptor common gamma chain (also known as CD132) is shared between the IL-2 or, IL-4 receptor, IL-7 receptor, IL-9 receptor, IL-13 receptor and IL-15 receptor.
IL-2 binds to the IL-2 receptor, which has three forms, generated by ent combinations of three ent proteins, often ed to as "chains": α, β and γ; these subunits are also parts of receptors for other cytokines. The β and γ chains of the IL- 2R are members of the type I ne receptor family.
The three receptor chains are expressed separately and differently on various cell types and can assemble in different combinations and orders to generate low, intermediate, and high affinity IL-2 receptors.
The α chain binds IL-2 with low affinity, the combination of β and γ together form a complex that binds IL-2 with intermediate affinity, primarily on memory T cells and NK cells; and all three receptor chains form a complex that binds IL-2 with high affinity (Kd ~ 10−11 M) on activated T cells and regulatory T cells.
The three IL-2 receptor chains span the cell membrane and extend into the cell, thereby ring biochemical signals to the cell interior. The alpha chain does not participate in signalling, but the beta chain is complexed with the tyrosine phosphatase JAK1.
Similarly the gamma chain complexes with another tyrosine kinase called JAK3. These enzymes are activated by IL-2 binding to the al domains of the IL-2R.
P108038PCT IL-2 signalling es the differentiation of T cells into effector T cells and into memory T cells when the initial T cells are also stimulated by an antigen. Through their role in the development of T cell immunologic memory, which depends upon the expansion of the number and function of n-selected T cell clones, they also have a key role in long-term cell-mediated immunity.
The chimeric cytokine receptor of the present invention may comprise the IL-2 receptor β-chain and/or the IL-2 or (i.e. common) γ-chain The amino acid sequences for the endodomains of the IL-2 β-chain and common γchain are shown as SEQ ID No. 1 and 2 SEQ ID No. 1: Endodomain derived from human common gamma chain: ERTMPRIPTLKNLEDLVTEYHGNFSAWSGVSKGLAESLQPDYSERLCLVSEIPPKGG ALGEGPGASPCNQHSPYWAPPCYTLKPET SEQ ID No. 2: Endodomain d from human IL-2Rβ: NCRNTGPWLKKVLKCNTPDPSKFFSQLSSEHGGDVQKWLSSPFPSSSFSPGGLAP EISPLEVLERDKVTQLLLQQDKVPEPASLSSNHSLTSCFTNQGYFFFHLPDALEIEAC QVYFTYDPYSEEDPDEGVAGAPTGSSPQPLQPLSGEDDAYCTFPSRDDLLLFSPSL LGGPSPPSTAPGGSGAGEERMPPSLQERVPRDWDPQPLGPPTPGVPDLVDFQPP PELVLREAGEEVPDAGPREGVSFPWSRPPGQGEFRALNARLPLNTDAYLSLQELQ GQDPTHLV The term "derived from" means that the endodomain of the chimeric cytokine receptor of the invention has the same sequence as the ype sequence of the endogenous molecule, or a variant thereof which retains the ability to form a complex with JAK-1 or JAK-3 and activate one of the signalling pathways mentioned above.
A "variant" sequence having at least 80, 85, 90, 95, 98 or 99% ce identity to the wild-type sequence (e.g. SEQ ID Nos. 1 or 2), providing that the variant sequence retains the function of the wild-type sequence i.e. the ability to form a complex with JAK-1 or JAK-3 and activate, for example, the JAK-STAT signalling pathway.
[Link] http://blast.ncbi.nlm.nih.gov/ P108038PCT The percentage identity between two polypeptide sequences may be readily determined by programs such as BLAST which is freely available at http://blast.ncbi.nlm.nih.gov.
IL-7 The interleukin-7 receptor is made up of two chains: the eukin-7 receptor-α chain ) and common-γ chain receptor (CD132). The common-γ chain receptors is shared with various cytokines, including interleukin-2, -4, -9, and -15. Interleukin-7 receptor is expressed on various cell types, including naive and memory T cells.
The interleukin-7 receptor plays a critical role in the development of cytes, especially in V(D)J recombination. IL-7R also controls the ibility of a region of the genome that ns the T-cell receptor gamma gene, by STAT5 and histone acetylation. Knockout studies in mice suggest that blocking apoptosis is an essential function of this protein during differentiation and activation of T lymphocytes.
The chimeric cytokine receptor of the present invention may comprise the IL-7 receptor α-chain and/or the IL-7 receptor (i.e. common) n, or a variant f.
The amino acid sequence for the endodomain of the IL-7 n is shown as SEQ ID No. 3.
SEQ ID No. 3 - Endodomain derived from human IL-7Rα: KKRIKPIVWPSLPDHKKTLEHLCKKPRKNLNVSFNPESFLDCQIHRVDDIQARDEVEG FLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACD APILSSSRSLDCRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQ PILTSLGSNQEEAYVTMSSFYQNQ IL-15 Interleukin 15 (IL-15) is a cytokine with structural similarity to IL-2. Like IL-2, IL-15 binds to and s through a complex composed of IL-2/IL-15 or beta chain (CD122) and the common gamma chain (gamma-C, CD132). IL-15 is secreted by mononuclear phagocytes (and some other cells) following viral infection. IL-15 induces cell proliferation of natural killer cells.
P108038PCT Interleukin-15 receptor consists of an interleukin 15 receptor alpha t and shares common beta and gamma ts with the IL-2 receptor.
SPACER The chimeric cytokine receptor of the present invention may comprise a spacer to connect the antigen-binding domain with the transmembrane domain and spatially te the antigen-binding domain from the endodomain. A flexible spacer allows to the antigen-binding domain to orient in different directions to enable antigen g.
Where the cell of the present ion comprises two or more chimeric cytokine receptors, the spacers may be the same or ent. Where the cell of the present invention comprises a chimeric cytokine receptor (CCR) and a chimeric antigen receptor (CAR), the spacer of the CCR and the CAR may be different, for example, having a different length. The spacer of the CAR may be longer than the spacer of the or each CCR.
The spacer sequence may, for example, comprise an IgG1 Fc region, an IgG1 hinge or a CD8 stalk. The linker may alternatively comprise an alternative linker sequence which has similar length and/or domain spacing properties as an IgG1 Fc region, an IgG1 hinge or a CD8 stalk.
A human IgG1 spacer may be altered to remove Fc binding motifs.
Examples of amino acid sequences for these spacers are given below: SEQ ID No. 4 (hinge-CH2CH3 of human IgG1) AEPKSPDKTHTCPPCPAPPVAGPSVFLFPPKPKDTLMIARTPEVTCVVVDVSHEDPE VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA LPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK SLSLSPGKKD SEQ ID No. 5 (human CD8 stalk): TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDI SEQ ID No. 6 (human IgG1 hinge): P108038PCT AEPKSPDKTHTCPPCPKDPK TRANSMEMBRANE DOMAIN The transmembrane domain is the sequence of a CCR that spans the membrane. It may comprise a hydrophobic alpha helix. The transmembrane domain may be derived from CD28, which gives good or stability.
Alternatively the transmembrane domain may be derived from a cytokine receptor, for example the same cytokine from which the endodomain is derived.
The transmembrane domain may, for example be derived from IL-2R, IL-7R or IL-15R.
SEQ ID No. 7 - Transmembrane derived from human common gamma chain: VVISVGSMGLIISLLCVYFWL SEQ ID No. 8 - Transmembrane derived from human IL-2Rβ: IPWLGHLLVGLSGAFGFIILVYLLI SEQ ID No. 9 - Transmembrane derived from human IL-7Rα: PILLTISILSFFSVALLVILACVLW SEQ ID No. 10 - embrane derived from human IL-15Rα: AISTSTVLLCGLSAVSLLACYL LIGAND-BINDING EXODOMAIN The ligand binding domain ses an antigen binding domain. The antigen g domain binds the target ligand for the CCR, i.e. the tumour secreted factor or chemokine or cell surface antigen.
Numerous antigen-binding domains are known in the art, including those based on the antigen binding site of an antibody, dy mimetics, and T-cell receptors. For example, the n-binding domain may comprise: a single-chain le fragment (scFv) derived from a monoclonal antibody; the binding domain from a natural receptor for the target antigen; a peptide with sufficient affinity for the target ligand; a single P108038PCT domain binder such as a camelid; an artificial binder single as a Darpin; or a singlechain derived from a T-cell receptor.
The term "ligand" is used synonymously with "antigen" to mean an entity which is specifically ised and bound by the n-binding domain of the CCR.
Where the ligand is a tumour secreted factor, the antigen g domain may comprise an immunoglobulin-based antigen binding site, such as an scFv or a single domain binder.
Where the ligand is a chemokine, the antigen binding domain may comprise the chemokine-binding portion of a natural receptor for the chemokine.
LIGAND The CCR of the present invention binds ligand.
The ligand may be a soluble ligand such as a tumour secreted factor or a chemokine. atively, the ligand may be a membrane bound ligand, such as a cell surface antigen.
The term "soluble ligand" is used to indicate a ligand or antigen which is not part of or attached to a cell but which moves freely in the ellular space, for e in a bodily fluid of the tissue of interest. The soluble ligand may exist in a cell-free state in the serum, plasma or other bodily fluid of an individual.
The soluble ligand may be associated with the presence or pathology of a particular disease, such as cancer.
The soluble ligand may be part of the cancer secretome, i.e. the collection of factors secreted by a tumour, be it from cancer stem cells, non-stem cells or the surrounding stroma. The soluble ligand may be secreted or shed by tumour cells (see next section).
The e ligand may be characteristic of a disease or of diseased tissue. It may be found exclusively, or at a higher level in a subject having the disease vs a healthy subject; or in diseased tissue vs healthy tissue. The soluble ligand may be expressed P108038PCT at at least a 2-fold, , 10-fold, ld, 1000-fold, 10,000-fold or 0 fold higher level a subject having the disease vs a healthy subject; or in diseased tissue vs healthy tissue.
The terms "cell-surface antigen" and "cell-surface ligand" is used synonymously with "membrane-bound antigen" and ane-bound ligand" to mean a ligand which is attached to or expressed on the surface of the cell. The cell-surface ligand may, for example, be a transmembrane protein.
The cell on which the cell-surface ligand is found may be a target cell, such as a cancer cell.
The cell-surface ligand may be ated with the presence or pathology of a particular disease, such as cancer. Alternatively the cell-surface ligand may be characteristic of the cell type of the target cell (e.g. B-cell) without being necessarily associated with the diseased state.
Where the cell-surface ligand is characteristic of a disease or of diseased tissue it may be found ively, or at a higher level on the nt cells a subject having the disease vs a healthy subject; or in diseased tissue vs healthy . The cell-surface ligand may be expressed at at least a 2-fold, 5-fold, 10-fold, 100-fold, 1000-fold, 10,000- fold or 100,000 fold higher level on a cell of a subject having the disease vs a healthy subject; or in diseased tissue vs healthy tissue.
TUMOUR SECRETED FACTOR The ligand recognised by the CCR may be a soluble ligand secreted by or shedded from a tumour.
This "tumour secreted factor" may, for example, be prostate-specificantigen (PSA), carcinoembryonic antigen (CEA), vascular endothelial growth factor (VEGF) or Cancer Antigen -125 (CA-125).
The tumour secreted factor may be a soluble ligand which is not a cytokine. The CCR of the present invention ore grafts the binding specificity for a non-cytokine ligand on to the endodomain of a ne receptor.
P108038PCT PROSTATE-SPECIFIC ANTIGEN (PSA) The soluble ligand may be prostate-specific antigen (PSA).
Prostate-specific antigen (PSA), also known as gamma-seminoprotein or kallikrein-3 (KLK3), is a glycoprotein enzyme encoded in humans by the KLK3 gene. PSA is a member of the kallikrein-related peptidase family and is ed by the epithelial cells of the prostate gland.
PSA is present in small ties in the serum of men with healthy prostates, but is elevated in individuals with prostate cancer and other te disorders.
PSA is a sidue glycoprotein and is activated by KLK2. Its physiological role is the liquefaction of the coagulum components of the semen leading to liberation of spermatozoa. In cancer, PSA may participate in the processes of neoplastic growth and metastasis.
PSA is a chymotrypsin-like serine protease with a typical His-Asp-Ser triad and a catalytic domain similar to those of other kallikrein-related peptidases. The crystal structure of PSA has been obtained i) in complex with the monoclonal antibody (mAb) 8G8F5 and ii) in a ch x with two mAbs 5D5A5 and 5D3D11 (Stura et al (J. Mol. Biol. (2011) 414:530-544).
Various monoclonal antibodies are known, including clones 2G2-B2, 2D8-E8, IgG1/K bed in Bavat et al Avicenna J. Med. Biotechnol. 2015, 7:2-7; and Leinonen (2004) 289:157-67.
The CCR of the present invention may, for example, comprise the 6 CDRs or the VH and/or VL domain(s) from a PSA-binding mAb such as 8G8F5, 5D5A5 or 5D3D11.
Where the CCR comprises two antigen binding specificities, g different epitopes on PSA, one may be bsed on, for example 5D3D11 and one may be based on, for example, 5D5A5.
The amino acid ces for 5D3D11 and 5D5A5 VH and VL are given below. The complementarity determining regions (CDRs) are highlighted in bold.
P108038PCT 5D3D11 VH (SEQ ID No. 11) QVQLQQSGPELVKPGASVKISCKVSGYAISSSWMNWVKQRPGQGLEWIGRIYPGD GDTKYNGKFKDKATLTVDKSSSTAYMQLSSLTSVDSAVYFCARDGYRYYFDYWGQ GTSVTVSS 5D3D11 VL (SEQ ID No. 12) DIVMTQTAPSVFVTPGESVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMS NLASGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCMQHLEYPVTFGAGTKVEIK 5D5A5 VH (SEQ ID No. 13) QVQLQQSGAELAKPGASVKMSCKTSGYSFSSYWMHWVKQRPGQGLEWIGYINPS TGYTENNQKFKDKVTLTADKSSNTAYMQLNSLTSEDSAVYYCARSGRLYFDVWGA GTTVTVSS 5D5A5 VL (SEQ ID No. 14) DIVLTQSPPSLAVSLGQRATISCRASESIDLYGFTFMHWYQQKPGQPPKILIYRASNL ESGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQTHEDPYTFGGGTKLEIK ScFv based on 5D5A5 (SEQ ID No. 15) QVQLQQSGAELAKPGASVKMSCKTSGYSFSSYWMHWVKQRPGQGLEWIGYINPS TGYTENNQKFKDKVTLTADKSSNTAYMQLNSLTSEDSAVYYCARSGRLYFDVWGA GTTVTVSSGGGGSGGGGSGGGGSGGGGSDIVLTQSPPSLAVSLGQRATISCRASE SIDLYGFTFMHWYQQKPGQPPKILIYRASNLESGIPARFSGSGSRTDFTLTINPVEAD DVATYYCQQTHEDPYTFGGGTKLEIK ScFv based on 5D3D11 (SEQ ID No. 16) QVQLQQSGPELVKPGASVKISCKVSGYAISSSWMNWVKQRPGQGLEWIGRIYPGD GDTKYNGKFKDKATLTVDKSSSTAYMQLSSLTSVDSAVYFCARDGYRYYFDYWGQ GTSVTVSSGGGGSGGGGSGGGGSGGGGSDIVMTQTAPSVFVTPGESVSISCRSS KSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLASGVPDRFSGSGSGTDFTLRISR VEAEDVGVYYCMQHLEYPVTFGAGTKVEIK Where a cell comprises two CCRs, the n-binding domain of the first CCR may comprise the 6 CDRs from 5D5A5 and the n-binding domain of the second CCR may comprise the 6 CDRs from 5D3D11.
P108038PCT The antigen-binding domain of the first CCR may comprise the VH and/or VL domain(s) from 5D5A5 or a variant thereof; and the antigen-binding domain of the second CCR may comprise the VH and/or VL domain(s) from 5D3D11 or a variant f. Variant VH and VL domains may have at least 80, 90, 95 or 99% identity to the sequences given above, provided that they retain PSA-binding activity.
A cell expressing a CCR which binds PSA may be useful in the treatment of prostate cancer.
CARCINOEMBRYONIC N (CEA) The soluble ligand may be CEA.
Carcinoembryonic antigen (CEA) describes a set of highly related glycoproteins involved in cell adhesion. CEA is ly produced in gastrointestinal tissue during fetal development, but the production stops before birth. Therefore CEA is usually present only at very low levels in the blood of healthy adults. However, the serum levels are raised in some types of cancer, which means that it can be used as a tumor marker in clinical tests.
CEA are glycosyl phosphatidyl inositol (GPI) cell surface anchored glycoproteins whose specialized sialofucosylated orms serve as functional colon carcinoma L- selectin and E-selectin ligands, which may be al to the metastatic ination of colon carcinoma cells. Immunologically they are characterized as members of the CD66 cluster of entiation.
CEA and related genes make up the CEA family belonging to the immunoglobulin superfamily. In , the carcinoembryonic antigen family consists of 29 genes, 18 of which are normally expressed. The following is a list of human genes which encode carcinoembryonic antigen-related cell adhesion proteins: CEACAM1, CEACAM3, CEACAM4, 5, CEACAM6, CEACAM7, CEACAM8, CEACAM16, CEACAM18, CEACAM19, CEACAM20, CEACAM21 s antibodies which target CEA are described in A cell expressing a CCR against CEA may be useful in the treatment of, for example, colorectal cancer.
P108038PCT VASCULAR ELIAL GROWTH FACTOR (VEGF) The soluble ligand may be VEGF.
Vascular endothelial growth factor (VEGF) is a signal protein produced by cells that stimulates vasculogenesis and angiogenesis. It is part of the system that restores the oxygen supply to tissues when blood circulation is inadequate. Serum concentration of VEGF is high in bronchial asthma and diabetes mellitus. VEGF's normal function is to create new blood vessels during embryonic development, new blood vessels after , muscle following exercise, and new vessels teral circulation) to bypass blocked vessels.
When VEGF is overexpressed, it can bute to disease. Solid cancers cannot grow beyond a limited size without an adequate blood ; cancers that can express VEGF are able to grow and metastasize.
VEGF is a sub-family of the platelet-derived growth factor family of cystine-knot growth factors. They are important signaling proteins involved in both vasculogenesis (the de novo formation of the embryonic circulatory system) and angiogenesis (the growth of blood vessels from pre-existing vasculature).
The VEGF family comprises in mammals five members: , placenta growth factor (PGF), VEGF-B, VEGF-C and VEGF-D. s antibodies to VEGF are known, such as bevacizumab (Avastin) and Ranibizumab (Lucentis).
CANCER ANTIGEN 125 (CA-125) CA-125 is associated with ovarian cancer and is the most frequently used ker for ovarian cancer detection. While CA-125 is best known as a marker for ovarian cancer, it may also be elevated in other cancers, including endometrial cancer, fallopian tube cancer, lung cancer, breast cancer and gastrointestinal cancer.
The sequence of human CA-125 (also known as mucin-16) is available from NCBI, ion No. 078966.
P108038PCT A number of CA125-binding monoclonal antibodies are known, including OC125 and M11 (Nustad et al 1996, Tumour Biol. 17:196-329). In this study the specificity of 26 monoclonal antibodies against the CA 125 antigen was investigated. It was found that the CA 125 antigen carries only two major antigenic domains, which classifies the antibodies as OC125-like (group A) or M11-like (group B).
The chimeric cytokine receptor of the present ion may comprise an nbinding domain from such an antibody. A cell comprising such a CCR may be useful in the treatment of, for example, ovarian cancer.
The tumour secreted factor (or, if in a membrane-bound form, the transmembrane n) may be selected from the following non-exhaustive list: ALK gene rearrangements and overexpression giving mutated forms of ALK proteins fetoprotein (AFP) Betamicroglobulin (B2M) Beta-human chorionic gonadotropin (Beta-hCG) BRAF V600 mutations giving mutated B-REF protein C-kit/CD117 /CA27.29 CA19-9 Calcitonin Chromogranin A (CgA) Cytokeratin fragment 21-1 EGFR gene mutation analysis en receptor (ER)/progesterone receptor (PR) Fibrin/fibrinogen HER2/neu gene amplification or protein overexpression Immunoglobulins KRAS gene mutation analysis Lactate dehydrogenase Neuron-specific enolase (NSE) Nuclear matrix protein 22 Programmed death ligand 1 (PD-L1) Thyroglobulin P108038PCT Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) CHEMOKINE Chemokines are chemotactic cytokines. Cell ion is guided by chemokine gradients embedded and immobilized in extracellular . The positively charged chemokines like CXCL12 bind to vely charged ECM molecules. These gradients provide tracks for cancer cell and immune cell homing. The action on T cells seems to be inhibitory for the homing of cytotoxic T cells, while regulatory T cells appear to be attracted.
Chemokines are imately 8-10 kilodaltons in mass and have four cysteine residues in conserved locations which are key to g their 3-dimensional shape.
Some chemokines are considered pro-inflammatory and can be induced during an immune response to recruit cells of the immune system to a site of infection, while others are considered tatic and are ed in controlling the migration of cells during normal processes of tissue maintenance or development.
Chemokines have been classified into four main subfamilies : CXC, CC, CX3C and XC.
All of these proteins exert their biological effects by interacting with G protein-linked transmembrane receptors called chemokine ors that are selectively found on the surfaces of their target cells.
The major role of chemokines is to act as a chemoattractant to guide the migration of cells. Cells that are attracted by chemokines follow a signal of increasing chemokine concentration towards the source of the chemokine. Some chemokines control cells of the immune system during processes of immune surveillance, such as directing lymphocytes to the lymph nodes so they can screen for invasion of pathogens by interacting with antigen-presenting cells residing in these tissues. Other chemokines are inflammatory and are released from a wide variety of cells in se to bacterial infection, viruses and other agents. Their release is often stimulated by lammatory cytokines such as interleukin 1. matory chemokines function mainly as chemoattractants for leukocytes, recruiting monocytes, neutrophils and other effector cells from the blood to sites of infection or tissue damage. Certain inflammatory chemokines activate cells to initiate an immune response or promote wound healing.
P108038PCT They are released by many different cell types and serve to guide cells of both innate immune system and adaptive immune system.
CC chemokines The CC chemokine (or β-chemokine)proteins have two adjacent cysteines (amino , near their amino terminus. There have been at least 27 distinct s of this subgroup reported for mammals, called CC chemokine ligands (CCL)-1 to -28; CCL10 is the same as CCL9. Chemokines of this ily usually contain four cysteines (C4- CC chemokines), but a small number of CC chemokines possess six cysteines (C6-CC chemokines). C6-CC chemokines include CCL1, CCL15, CCL21, CCL23 and CCL28.
CC chemokines induce the migration of monocytes and other cell types such as NK cells and dendritic cells.
Examples of CC chemokine e monocyte chemoattractant n-1 (MCP-1 or CCL2) which induces monocytes to leave the bloodstream and enter the surrounding tissue to become tissue macrophages.
CCL5 (or RANTES) attracts cells such as T cells, eosinophils and basophils that express the receptor CCR5.
CXC chemokines The two N-terminal cysteines of CXC chemokines (or α-chemokines) are separated by one amino acid, represented in this name with an "X". There have been 17 different CXC chemokines described in mammals, that are subdivided into two categories, those with a specific amino acid sequence (or motif) of glutamic acid-leucine-arginine (or ELR for short) immediately before the first cysteine of the CXC motif (ELR-positive), and those without an ELR motif (ELR-negative). sitive CXC chemokines specifically induce the ion of neutrophils, and interact with chemokine receptors CXCR1 and CXCR2.
C ines The third group of chemokines is known as the C chemokines (or γ chemokines), and is unlike all other chemokines in that it has only two cysteines; one inal cysteine and one cysteine downstream. Two chemokines have been described for this subgroup and are called XCL1 (lymphotactin-α) and XCL2 (lymphotactin-β).
CX3C chemokine P108038PCT CX3C ines have three amino acids between the two cysteines. The only CX3C chemokine discovered to date is called fractalkine (or CX3CL1). It is both secreted and tethered to the surface of the cell that expresses it, thereby serving as both a chemoattractant and as an adhesion le.
Chemokine receptors are G protein-coupled receptors containing 7 transmembrane domains that are found on the surface of ytes. Approximately 19 different ine receptors have been characterized to date, which are divided into four es depending on the type of chemokine they bind; CXCR that bind CXC chemokines, CCR that bind CC chemokines, CX3CR1 that binds the sole CX3C chemokine (CX3CL1), and XCR1 that binds the two XC ines (XCL1 and XCL2).
They share many structural features; they are similar in size (with about 350 amino acids), have a short, acidic N-terminal end, seven helical transmembrane domains with three intracellular and three extracellular hydrophilic loops, and an intracellular C- terminus containing serine and threonine residues important for receptor regulation.
The first two extracellular loops of chemokine receptors each has a ved cysteine residue that allow formation of a disulfide bridge between these loops. G proteins are coupled to the C-terminal end of the chemokine receptor to allow intracellular signaling after receptor activation, while the N-terminal domain of the chemokine receptor determines ligand binding specificity.
CXCL12 CXCL12 is strongly chemotactic for cytes. CXCL12 plays an important role in angiogenesis by recruiting endothelial progenitor cells (EPCs) from the bone marrow through a CXCR4 ent ism. It is this function of CXCL12 that makes it a very important factor in carcinogenesis and the cularisation linked to tumour progression. CXCL12 also has a role in tumour metastasis where cancer cells that s the receptor CXCR4 are attracted to metastasis target tissues that release the ligand, CXCL12.
The receptor for CXCL12 is CXCR4. The CCR of the present invention may comprise the CXCL12-binding domain from CXCR4 linked to an endodomain derived from a cytokine receptor, such as the IL-2 receptor.
CXCR4 coupled expression of IL2 would support engraftment of therapeutic T cell for cancer therapies. In multiple myeloma, a cell expressing such a CCR may mobilize P108038PCT cells and change the bone marrow environment. Such cells also have uses in the treatment of solid cancers by modifying the solid tumour microenvironment.
The amino acid sequence for CXCR4 is shown below as SEQ ID No. 17 SEQ ID No. 17 1 msiplpllqi ytsdnyteem smke pcfreenanf nkiflptiys iifltgivgn 61 glvilvmgyq kklrsmtdky rlhlsvadll fwav davanwyfgn flckavhviy 121 tvnlyssvli lafisldryl aivhatnsqr prkllaekvv yvgvwipall ltipdfifan 181 vseaddryic drfypndlwv vvfqfqhimv glilpgivil scyciiiskl shskghqkrk 241 alkttvilil affacwlpyy igisidsfil leiikqgcef entvhkwisi tealaffhcc 301 aflg akfktsaqha gssl kilskgkrgg hssvsteses ssfhss CXCR7 also binds CXCL12.
The chemokine (C-C motif) ligand 2 (CCL2) is also referred to as monocyte chemotactic protein 1 (MCP1) and small ble cytokine A2. CCL2 recruits monocytes, memory T cells, and tic cells to the sites of inflammation produced by either tissue injury or infection.
CCR2 and CCR4 are two cell surface receptors that bind CCL2.
CCR2 has the amino acid sequence shown as SEQ ID No. 18 SEQ ID No. 18 1 mlstsrsrfi rntnesgeev ttffdydyga pchkfdvkqi gaqllpplys lvfifgfvgn 61 mlvvlilinc tdiy llnlaisdll flitlplwah saanewvfgn amcklftgly 121 higyfggiff iilltidryl aivhavfalk gvvt svitwlvavf asvpgiiftk 181 cqkedsvyvc gpyfprgwnn fhtimrnilg lvlpllimvi cysgilktll rcrnekkrhr 241 avrviftimi tpyn ivillntfqe ffglsncest sqldqatqvt etlgmthcci 301 npiiyafvge kfrslfhial gcriaplqkp vcggpgvrpg knvkvttqgl ldgrgkgksi 361 grapeaslqd kega CCR4 has the amino acid sequence shown as SEQ ID No. 19.
P108038PCT SEQ ID No. 19 1 mnptdiadtt ldesiysnyy lyesipkpct kegikafgel flpplyslvf vfgllgnsvv 61 vlvlfkykrl rsmtdvylln lfvf yyaa dqwvfglglc kmiswmylvg 121 fysgiffvml msidrylaiv havfslrart tsla twsvavfasl pgflfstcyt 181 ernhtycktk twkv lssleinilg lviplgimlf cysmiirtlq hcknekknka 241 vkmifavvvl flgfwtpyni vlfletlvel evlqdctfer yldyaiqate tlafvhccln 301 piiyfflgek frkyilqlfk tcrglfvlcq ycgllqiysa dtpsssytqs tmdhdlhdal The CCR of the present invention may comprise the CCL2 binding site of CCR2 or CCR4 in its ligand binding .
CELL-SURFACE ANTIGEN The ligand may be a cell-surface antigen, such as a transmembrane protein.
The cell surface antigen may be CD22.
CD22, or cluster of differentiation-22, is a molecule belonging to the SIGLEC family of lectins. It is found on the surface of mature B cells and to a lesser extent on some immature B cells. lly speaking, CD22 is a regulatory molecule that prevents the overactivation of the immune system and the pment of autoimmune diseases.
CD22 is a sugar binding transmembrane protein, which specifically binds sialic acid with an immunoglobulin (Ig) domain located at its N-terminus. The presence of Ig domains makes CD22 a member of the immunoglobulin superfamily. CD22 functions as an inhibitory receptor for B cell receptor (BCR) signalling. sed expression of CD22 is seen in non-Hodgkin and other lymphomas. Various monoclonal antibodies targeting CD22 are known, including zumab, inotuzumab ozogamicin, m971 and m972.
CHIMERIC ANTIGEN RECEPTORS (CAR) The cell of the present invention may also comprise one or more chimeric antigen receptor(s). The CAR(s) may be specific for a tumour-associated antigen.
P108038PCT Classical CARs are chimeric type I trans-membrane proteins which connect an ellular antigen-recognizing domain (binder) to an intracellular signalling domain (endodomain). The binder is typically a single-chain variable nt (scFv) derived from a monoclonal antibody (mAb), but it can be based on other s which comprise an antibody-like or ligand-based antigen g site. A trans-membrane domain anchors the protein in the cell membrane and connects the spacer to the endodomain.
Early CAR designs had endodomains d from the ellular parts of either the γ chain of the FcεR1 or CD3ζ. Consequently, these first generation receptors transmitted immunological signal 1, which was sufficient to trigger T-cell killing of cognate target cells but failed to fully activate the T-cell to proliferate and survive. To overcome this limitation, compound endodomains have been constructed: fusion of the intracellular part of a T-cell co-stimulatory le to that of CD3ζ results in second generation receptors which can it an activating and co-stimulatory signal simultaneously after antigen ition. The co-stimulatory domain most commonly used is that of CD28. This supplies the most potent co-stimulatory signal - namely immunological signal 2, which triggers T-cell proliferation. Some receptors have also been described which include TNF receptor family endodomains, such as the closely related OX40 and 41BB which transmit survival signals. Even more potent third generation CARs have now been described which have endodomains capable of transmitting activation, proliferation and survival signals.
CAR-encoding nucleic acids may be transferred to T cells using, for example, retroviral s. In this way, a large number of antigen-specific T cells can be generated for adoptive cell er. When the CAR binds the target-antigen, this results in the transmission of an activating signal to the T-cell it is expressed on. Thus the CAR directs the specificity and cytotoxicity of the T cell towards cells expressing the targeted antigen.
The cell of the present invention may comprise one or more CAR(s).
The CAR(s) may comprise an antigen-binding domain, a spacer domain, a transmembrane domain and an main. The endodomain may comprise or associate with a domain which transmit T-cell activation signals.
CAR N BINDING DOMAIN P108038PCT The antigen-binding domain is the portion of a CAR which recognizes antigen.
Numerous antigen-binding domains are known in the art, including those based on the antigen g site of an antibody, antibody mimetics, and T-cell receptors. For example, the antigen-binding domain may comprise: a -chain variable fragment (scFv) derived from a monoclonal antibody; a l ligand of the target antigen; a peptide with sufficient affinity for the target; a single domain binder such as a camelid; an artificial binder single as a Darpin; or a single-chain derived from a T-cell receptor.
The term "ligand" is used synonymously with "antigen" to mean an entity which is specifically ised and bound by the antigen-binding domain of a CAR.
CELL SURFACE ANTIGEN The CAR may recognise a cell-surface n, i.e. an entity, such as a transmembrane protein which is expressed on the surface of a target cell, such as a tumour cell.
The CAR may specifically bind a tumour-associated cell-surface antigen.
Various tumour associated antigens (TAA) are known, some of which are shown in Table 1. The antigen-binding domain used in the present invention may be a domain which is capable of binding a TAA as ted therein.
Table 1 Cancer type TAA Diffuse Large B-cell Lymphoma CD19, CD20, CD22 Breast cancer ErbB2, MUC1 AML CD13, CD33 Neuroblastoma GD2, NCAM, ALK, GD2 B-CLL CD19, CD52, CD160 Colorectal cancer Folate binding protein, CA-125 Chronic cytic Leukaemia CD5, CD19 Glioma EGFR, Vimentin Multiple myeloma BCMA, CD138 Renal Cell Carcinoma ic anhydrase IX, G250 P108038PCT te cancer PSMA Bowel cancer A33 Where the CAR recognises a B-cell lymphoma or leukemia antigen (such as CD19, CD20, CD52, CD160 or CD5), the CCR may recognise another B-cell antigen, such as CD22.
PROSTATE-CANCER ASSOCIATED NS The CAR may specifically bind a cell-surface antigen associated with prostate cancer, such as prostate stem cell antigen (PSCA) or prostate-specific membrane antigen (PSMA).
PSCA is a glycosylphosphatidylinositol-anchored cell membrane glycoprotein. It is is up-regulated in a large proportion of prostate cancers and is also detected in cancers of the bladder and pancreas.
Various anti-PSCA antibodies are known, such as 7F5 (Morgenroth et al (Prostate (2007) 67:1121-1131); 1G8 rdal et al (2014) BMC Cancer 14:30); and 117 (Abate-Daga et al (2014) 25:1003-1012).
The CCR-expressing cell of the invention may also express an SCA CAR which may comprise an antigen binding domain based on one of these antibodies.
PSMA is is a zinc metalloenzyme that resides in membranes. PSMA is strongly expressed in the human prostate, being a hundredfold r than the expression in most other tissues. In cancer, it is upregulated in expression and has been called the second-most-upregulated gene in prostate cancer, with increase of 8- to 12-fold over the noncancerous prostate. In addition to the expression in the human prostate and prostate , PSMA is also found to be highly sed in tumor culature but not normal vasculature of all types of solid tumors, such as kidney, breast, colon, etc.
Various anti-PSMA antibodies are known, such as 7E11, J591, J415, and Hybritech PEQ226.5 and PM2J004.5 each of which binds a distinct epitope of PSMA (Chang et al (1999) Cancer Res 15:3192-8).
P108038PCT The CCR-expressing cell of the invention may also express an anti-PSMA CAR which may comprise an n binding domain based on one of these antibodies.
For example, the CCR may comprise an scFv based on J591, having the sequence shown as SEQ ID No. 20.
SEQ ID No. 20 (J591 scFv) EVQLQQSGPELKKPGTSVRISCKTSGYTFTEYTIHWVKQSHGKSLEWIGNINPNNG GTTYNQKFEDKATLTVDKSSSTAYMELRSLTSEDSAVYYCAAGWNFDYWGQGTTL TVSSGGGGSGGGGSGGGGSDIVMTQSHKFMSTSVGDRVSIICKASQDVGTAVDW YQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTITNVQSEDLADYFCQQY FGAGTMLDLKR CAR TRANSMEMBRANE DOMAIN The transmembrane domain is the sequence of a CAR that spans the membrane. It may comprise a hydrophobic alpha helix. The CAR transmembrane domain may be derived from CD28, which gives good or stability.
CAR SIGNAL PEPTIDE The CAR and CCR described herein may comprise a signal peptide so that when it/they is expressed in a cell, such as a T-cell, the nascent protein is directed to the endoplasmic reticulum and subsequently to the cell e, where it is sed.
The core of the signal peptide may contain a long stretch of hydrophobic amino acids that has a tendency to form a single alpha-helix. The signal peptide may begin with a short positively charged h of amino acids, which helps to enforce proper topology of the polypeptide during ocation. At the end of the signal peptide there is typically a stretch of amino acids that is recognized and cleaved by signal peptidase. Signal peptidase may cleave either during or after completion of translocation to generate a free signal peptide and a mature protein. The free signal peptides are then digested by specific proteases.
The signal peptide may be at the amino terminus of the molecule.
P108038PCT The signal peptide may comprise the sequence shown as SEQ ID No. 21, 22 or 23 or a variant thereof having 5, 4, 3, 2 or 1 amino acid mutations (insertions, substitutions or additions) provided that the signal peptide still functions to cause cell surface expression of the CAR.
SEQ ID No. 21: MGTSLLCWMALCLLGADHADG The signal peptide of SEQ ID No. 21 is t and highly efficient and is derived from TCR beta chain. It is predicted to give about 95% cleavage after the terminal glycine, giving ent removal by signal peptidase.
SEQ ID No. 22: MSLPVTALLLPLALLLHAARP The signal peptide of SEQ ID No. 22 is derived from IgG1.
SEQ ID No. 23: MAVPTQVLGLLLLWLTDARC The signal peptide of SEQ ID No. 23 is derived from CD8a.
CAR MAIN The endodomain is the portion of a classical CAR which is located on the intracellular side of the membrane.
The endodomain is the signal-transmission portion of a classical CAR. After antigen recognition by the antigen binding domain, individual CAR molecules cluster, native CD45 and CD148 are excluded from the synapse and a signal is transmitted to the cell.
The CAR endodomain may be or comprise an ellular ling domain. In an alternative embodiment, the endodomain of the t CAR may be e of interacting with an intracellular signalling molecule which is present in the cytoplasm, leading to signalling.
The ellular signalling domain or separate intracellular signalling molecule may be or comprise a T cell signalling domain.
P108038PCT The most commonly used signalling domain component is that of CD3-zeta main, which contains 3 ITAMs. This transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signalling may be needed. For example, chimeric CD28 and OX40 can be used with CD3-Zeta to transmit a proliferative / survival signal, or all three can be used together.
The CAR may comprise the CD3-Zeta endodomain alone, the CD3-Zeta main with that of either CD28 or OX40 or the CD28 endodomain and OX40 and CD3-Zeta endodomain.
The CAR endodomain may comprise one or more of the following: an ICOS endodomain, a CD27 endodomain, a BTLA main, a CD30 main, a GITR endodomain and an HVEM endodomain.
The endomain may comprise the sequence shown as SEQ ID No. 24 to 32 or a variant thereof having at least 80% sequence identity.
SEQ ID No. 24 - CD3 Z endodomain RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNP ELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQAL SEQ ID No. 25 - CD28 and CD3 Zeta endodomains SKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQ GQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAE AYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR SEQ ID No. 26 - CD28, OX40 and CD3 Zeta mains SKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRDQRLPPDAHKPPG GGSFRTPIQEEQADAHSTLAKIRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDV LDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDG LYQGLSTATKDTYDALHMQALPPR SEQ ID No. 27 - ICOS endodomain CWLTKKKYSSSVHDPNGEYMFMRAVNTAKKSRLTDVTL P108038PCT SEQ ID No. 28 - CD27 endodomain QRRKYRSNKGESPVEPAEPCHYSCPREEEGSTIPIQEDYRKPEPACSP SEQ ID No. 29 - BTLA endodomain RRHQGKQNELSDTAGREINLVDAHLKSEQTEASTRQNSQVLLSETGIYDNDPDLCF RMQEGSEVYSNPCLEENKPGIVYASLNHSVIGPNSRLARNVKEAPTEYASICVRS SEQ ID No. 30 - CD30 endodomain KRIRQKLHLCYPVQTSQPKLELVDSRPRRSSTQLRSGASVTEPVAEERGL MSQPLMETCHSVGAAYLESLPLQDASPAGGPSSPRDLPEPRVSTEHTNNKIEKIYIM VGTVKAELPEGRGLAGPAEPELEEELEADHTPHYPEQETEPPLGSCSDVML SVEEEGKEDPLPTAASGK SEQ ID No. 31 - GITR endodomain QLGLHIWQLRSQCMWPRETQLLLEVPPSTEDARSCQFPEEERGERSAEEKGRLGD SEQ ID No. 32 - HVEM endodomain CVKRRKPRGDVVKVIVSVQRKRQEAEGEATVIEALQAPPDVTTVAVEETIPSFTGRS PNH A variant sequence may have at least 80%, 85%, 90%, 95%, 98% or 99% sequence identity to SEQ ID No. 24 to 32, provided that the sequence provides an effective intracellular signalling domain.
NUCLEIC ACID The present invention also provides a nucleic acid encoding a CCR of the invention.
The nucleic acid may have the structure: acer-TM-endo in which AgB1 is a nucleic acid sequence encoding the antigen-binding domain of the CCR; spacer 1 is a nucleic acid sequence encoding the spacer of the CCR; TM1 is a a nucleic acid sequence encoding the transmembrane domain of the CCR; P108038PCT endo 1 is a nucleic acid sequence encoding the endodomain of the CCR.
NUCLEIC ACID CONSTRUCT The t invention further provides a nucleic acid construct which comprises a first nucleic acid sequence encoding a first CCR as defined in connection with the first aspect of the invention; and a second nucleic acid sequence encoding a second CCR as defined in connection with the first aspect of the invention.
The nucleic acid construct may have the following structure: AgB1-spacer1-TM1-endo1-coexpr-AgB2-spacer2-TM2-endo2 in which AgB1 is a nucleic acid sequence encoding the antigen-binding domain of the first CCR; spacer 1 is a nucleic acid sequence encoding the spacer of the first CCR; TM1 is a a nucleic acid sequence encoding the transmembrane domain of the first endo 1 is a nucleic acid sequence encoding the main of the first CCR; coexpr is a nucleic acid sequence enabling co-expression of both CCRs AgB2 is a nucleic acid sequence ng the antigen-binding domain of the second spacer 2 is a nucleic acid sequence encoding the spacer of the second CCR; TM2 is a a nucleic acid sequence encoding the transmembrane domain of the second CCR; endo 2 is a nucleic acid sequence ng the main of the second CCR.
When the nucleic acid construct is sed in a cell, such as a T-cell, it encodes a polypeptide which is cleaved at the cleavage site such that the first and second CCRs are ressed at the cell e.
The first and second CCRs may bind distinct epitopes on the same antigen.
The first and second CCRs may have complementary endodomains e.g. one derived from the α or β chain of a cytokine receptor and one derived from the γ chain of the same cytokine receptor.
P108038PCT The present invention also provides a nucleic acid construct encoding a CCR of the invention and a CAR. Such a construct may have the structure: CCRAgB-CCRspacer-CCRTM-CCRendo-coexpr-CARAgB-CARspacer-CARTM- o -CARspacer-CARTM-CARendo-coexpr-CCRAgB-CCRspacer-CCRTM- CCRendo in which CCRAgB is a nucleic acid sequence encoding the antigen-binding domain of the CCR; CCRspacer is a nucleic acid sequence ng the spacer of the CCR; CCRTM is a a nucleic acid sequence encoding the embrane domain of the CCR; CCRendo is a nucleic acid ce encoding the endodomain of the CCR; coexpr is a nucleic acid sequence enabling co-expression of both the CCR and the CARAgB is a nucleic acid sequence encoding the antigen-binding domain of the CAR; CARspacer is a nucleic acid sequence encoding the spacer of the CAR; CARTM is a nucleic acid sequence encoding the transmembrane domain of the CAR; o is a nucleic acid sequence encoding the endodomain of the CAR.
The present invention also provides a c acid construct encoding a first and a second CCR of the invention and a CAR. The first and second CCRs may bind separate epitopes on the same antigen. Such a construct may have the structure: (i) CCRAgB1-CCRspacer1-CCRTM1-CCRendo1-coexpr1-CCRAgB2-CCRspacer2- CCRTM2-CCRendo2-coexpr2-CARAgB-CARspacer-CARTM-CARendo; (ii) CCRAgB1-CCRspacer1-CCRTM1-CCRendo1-coexpr1-CARAgB-CARspacer- CARTM-CARendo-coexpr2-CCRAgB2-CCRspacer2-CCRTM2-CCRendo2; or (iii) CARAgB-CARspacer-CARTM-CARendo-coexpr1-CCRAgB1-CCRspacer1- CCRTM1-CCRendo1-coexpr2-CCRAgB2-CCRspacer2-CCRTM2-CCRendo2; P108038PCT in which CCRAgB1 is a nucleic acid sequence ng the antigen-binding domain of the first CCRspacer1 is a nucleic acid sequence encoding the spacer of the first CCR; CCRTM1 is a nucleic acid sequence encoding the transmembrane domain of the first CCRendo1 is a nucleic acid sequence encoding the endodomain of the first CCR; CCRAgB2 is a nucleic acid sequence encoding the antigen-binding domain of the second CCR; CCRspacer2 is a nucleic acid sequence encoding the spacer of the second CCR; CCRTM2 is a nucleic acid sequence ng the transmembrane domain of the second CCR; CCRendo2 is a nucleic acid sequence encoding the endodomain of the second CCR; 1 and coexpr2 are nucleic acid sequences ng co-expression of the two flanking sequences; CARAgB is a nucleic acid sequence encoding the antigen-binding domain of the CAR; CARspacer is a nucleic acid sequence encoding the spacer of the CAR; CARTM is a nucleic acid sequence encoding the transmembrane domain of the CAR; CARendo is a nucleic acid sequence encoding the endodomain of the CAR.
As used , the terms "polynucleotide", "nucleotide", and "nucleic acid" are intended to be synonymous with each other.
It will be understood by a skilled person that numerous different cleotides and nucleic acids can encode the same ptide as a result of the degeneracy of the genetic code. In addition, it is to be understood that d persons may, using routine techniques, make nucleotide substitutions that do not affect the ptide sequence encoded by the polynucleotides described here to reflect the codon usage of any particular host organism in which the polypeptides are to be expressed.
Nucleic acids according to the ion may comprise DNA or RNA. They may be single-stranded or double-stranded. They may also be cleotides which include within them synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones, addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For the purposes of the use P108038PCT as described herein, it is to be tood that the polynucleotides may be modified by any method available in the art. Such modifications may be carried out in order to enhance the in vivo activity or life span of polynucleotides of interest.
The terms "variant", "homologue" or "derivative" in relation to a nucleotide sequence include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence.
In the structure above, "coexpr" is a nucleic acid sequence enabling co-expression of both first and second CARs. It may be a sequence ng a cleavage site, such that the nucleic acid construct produces comprises two or more CCRs, or a CCR and a CAR, joined by a cleavage site(s). The cleavage site may be self-cleaving, such that when the polypeptide is produced, it is ately cleaved into individual peptides without the need for any al cleavage activity.
The cleavage site may be any sequence which enables the first and second CCRs, or CCR and CAR, to become separated.
The term "cleavage" is used herein for ience, but the ge site may cause the peptides to separate into individual entities by a mechanism other than classical cleavage. For example, for the nd-Mouth disease virus (FMDV) 2A self-cleaving e (see below), various models have been proposed for to account for the "cleavage" activity: proteolysis by a host-cell proteinase, autoproteolysis or a translational effect (Donnelly et al (2001) J. Gen. Virol. 82:1027-1041). The exact mechanism of such "cleavage" is not important for the purposes of the present invention, as long as the cleavage site, when positioned between nucleic acid sequences which encode proteins, causes the proteins to be expressed as te entities.
The cleavage site may be a furin cleavage site.
Furin is an enzyme which belongs to the subtilisin-like proprotein convertase family.
The members of this family are tein convertases that process latent precursor proteins into their ically active products. Furin is a calcium-dependent serine endoprotease that can efficiently cleave precursor proteins at their paired basic amino acid processing sites. Examples of furin substrates include athyroid hormone, transforming growth factor beta 1 precursor, proalbumin, pro-beta-secretase, P108038PCT membrane type-1 matrix metalloproteinase, beta subunit of rve growth factor and von Willebrand factor. Furin cleaves proteins just downstream of a basic amino acid target sequence (canonically, Arg-X-(Arg/Lys)-Arg') and is enriched in the Golgi apparatus.
The cleavage site may be a Tobacco Etch Virus (TEV) ge site.
TEV se is a highly sequence-specific cysteine protease which is chymotrypsinlike proteases. It is very specific for its target cleavage site and is therefore frequently used for the controlled cleavage of fusion proteins both in vitro and in vivo. The consensus TEV cleavage site is ENLYFQ\S (where ‘\’ denotes the cleaved peptide bond). Mammalian cells, such as human cells, do not s TEV protease. Thus in embodiments in which the present nucleic acid construct comprises a TEV cleavage site and is expressed in a mammalian cell – exogenous TEV protease must also expressed in the mammalian cell.
The cleavage site may encode a self-cleaving peptide.
A cleaving peptide’ refers to a peptide which functions such that when the polypeptide comprising the proteins and the self-cleaving peptide is produced, it is immediately "cleaved" or separated into distinct and discrete first and second polypeptides without the need for any external cleavage activity.
The self-cleaving peptide may be a 2A self-cleaving peptide from an aphtho- or a cardiovirus. The primary 2A/2B ge of the aptho- and cardioviruses is mediated by 2A "cleaving" at its own C-terminus. In apthoviruses, such as foot-and-mouth disease s (FMDV) and equine rhinitis A virus, the 2A region is a short section of about 18 amino acids, which, together with the N-terminal residue of protein 2B (a conserved proline e) represents an autonomous t capable of mediating "cleavage" at its own C-terminus (Donelly et al (2001) as above). "2A-like" sequences have been found in picornaviruses other than aptho- or cardioviruses, ‘picornavirus-like’ insect viruses, type C rotaviruses and ed sequences within Trypanosoma spp and a bacterial sequence lly et al (2001) as above). The cleavage site may comprise one of these 2A-like sequences, such as: YHADYYKQRLIHDVEMNPGP (SEQ ID No. 33) HYAGYFADLLIHDIETNPGP (SEQ ID No. 34) QCTNYALLKLAGDVESNPGP (SEQ ID No. 35) ATNFSLLKQAGDVEENPGP (SEQ ID No. 36) AARQMLLLLSGDVETNPGP (SEQ ID No. 37) RAEGRGSLLTCGDVEENPGP (SEQ ID No. 38) TRAEIEDELIRAGIESNPGP (SEQ ID No. 39) TRAEIEDELIRADIESNPGP (SEQ ID No. 40) AKFQIDKILISGDVELNPGP (SEQ ID No. 41) SSIIRTKMLVSGDVEENPGP (SEQ ID No. 42) CDAQRQKLLLSGDIEQNPGP (SEQ ID No. 43) YPIDFGGFLVKADSEFNPGP (SEQ ID No. 44) The cleavage site may comprise the 2A-like ce shown as SEQ ID No. 38 (RAEGRGSLLTCGDVEENPGP).
The present invention also es a kit comprising one or more nucleic acid sequence(s) encoding first and second CCRs according to the first aspect of the present invention, or one or more CCR(s) according to the invention and one or more CAR(s).
SEQ ID NOS 45 and 46 give the complete amino acid sequences of a fusion between and anti-PSMA CAR and an anti-PSA CCR. Subheadings are given to label each portion of the sequence but in practice the various elements are connected giving one continuous ce.
The nucleic acid construct of the invention may encode a fusion protein as shown in SEQ ID No. 45 or 46.
SEQ ID NO. 45 - rative construct with IL-2R beta chain Signal sequence derived from human CD8a: MSLPVTALLLPLALLLHAA scFv aPSMA (J591 H/L) EVQLQQSGPELKKPGTSVRISCKTSGYTFTEYTIHWVKQSHGKSLEWIGNINPNNG GTTYNQKFEDKATLTVDKSSSTAYMELRSLTSEDSAVYYCAAGWNFDYWGQGTTL TVSSGGGGSGGGGSGGGGSDIVMTQSHKFMSTSVGDRVSIICKASQDVGTAVDW P108038PCT YQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTITNVQSEDLADYFCQQY NSYPLTFGAGTMLDLKR Linker Human IgG1Fc spacer (HCH2CH3pvaa): EPKSPDKTHTCPPCPAPPVAGPSVFLFPPKPKDTLMIARTPEVTCVVVDVSHEDPEV KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL PAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNG QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK Transmembrane derived from human CD28: FWVLVVVGGVLACYSLLVTVAFIIFWV main derived from TCRz: RRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKN PQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQA 2A peptide from Thosea asigna virus capsid protein: RAEGRGSLLTCGDVEENPGP Signal sequence derived from mouse kappa VIII: METDTLILWVLLLLVPGSTG scFv aPSA (5D5A5 H/L): QVQLQQSGAELAKPGASVKMSCKTSGYSFSSYWMHWVKQRPGQGLEWIGYINPS TGYTENNQKFKDKVTLTADKSSNTAYMQLNSLTSEDSAVYYCARSGRLYFDVWGA GTTVTVSSGGGGSGGGGSGGGGSGGGGSDIVLTQSPPSLAVSLGQRATISCRASE SIDLYGFTFMHWYQQKPGQPPKILIYRASNLESGIPARFSGSGSRTDFTLTINPVEAD DVATYYCQQTHEDPYTFGGGTKLEIK Linker: Human CD8aSTK spacer: RPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDI Transmembrane derived from human common gamma chain: VVISVGSMGLIISLLCVYFWL Endodomain derived from human common gamma chain: ERTMPRIPTLKNLEDLVTEYHGNFSAWSGVSKGLAESLQPDYSERLCLVSEIPPKGG ALGEGPGASPCNQHSPYWAPPCYTLKPET 2A peptide from equine is A virus polyprotein: QCTNYALLKLAGDVESNPGP Signal sequence derived from mouse kappa VIII: METDTLILWVLLLLVPGSTG scFv aPSA (5D3D11 H/L): QVQLQQSGPELVKPGASVKISCKVSGYAISSSWMNWVKQRPGQGLEWIGRIYPGD GKFKDKATLTVDKSSSTAYMQLSSLTSVDSAVYFCARDGYRYYFDYWGQ GTSVTVSSGGGGSGGGGSGGGGSGGGGSDIVMTQTAPSVFVTPGESVSISCRSS KSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLASGVPDRFSGSGSGTDFTLRISR VEAEDVGVYYCMQHLEYPVTFGAGTKVEIK Linker: SDPA Human CD28STK spacer: KIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKP Transmembrane derived from human : IPWLGHLLVGLSGAFGFIILVYLLI Endodomain derived from human IL-2Rβ: NCRNTGPWLKKVLKCNTPDPSKFFSQLSSEHGGDVQKWLSSPFPSSSFSPGGLAP EISPLEVLERDKVTQLLLQQDKVPEPASLSSNHSLTSCFTNQGYFFFHLPDALEIEAC QVYFTYDPYSEEDPDEGVAGAPTGSSPQPLQPLSGEDDAYCTFPSRDDLLLFSPSL LGGPSPPSTAPGGSGAGEERMPPSLQERVPRDWDPQPLGPPTPGVPDLVDFQPP PELVLREAGEEVPDAGPREGVSFPWSRPPGQGEFRALNARLPLNTDAYLSLQELQ GQDPTHLV SEQ ID No. 46 – Illustrative construct with IL-7R alpha chain Signal sequence derived from human CD8a: MSLPVTALLLPLALLLHAA scFv aPSMA (J591 H/L) EVQLQQSGPELKKPGTSVRISCKTSGYTFTEYTIHWVKQSHGKSLEWIGNINPNNG GTTYNQKFEDKATLTVDKSSSTAYMELRSLTSEDSAVYYCAAGWNFDYWGQGTTL TVSSGGGGSGGGGSGGGGSDIVMTQSHKFMSTSVGDRVSIICKASQDVGTAVDW YQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTITNVQSEDLADYFCQQY NSYPLTFGAGTMLDLKR Linker Human IgG1Fc spacer H3pvaa): EPKSPDKTHTCPPCPAPPVAGPSVFLFPPKPKDTLMIARTPEVTCVVVDVSHEDPEV KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL P108038PCT PAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNG QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK embrane derived from human CD28: VGGVLACYSLLVTVAFIIFWV Endodomain derived from TCRz: RRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKN PQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQA 2A peptide from Thosea asigna virus capsid n: RAEGRGSLLTCGDVEENPGP Signal sequence derived from mouse kappa VIII: METDTLILWVLLLLVPGSTG scFv aPSA (5D5A5 H/L): SGAELAKPGASVKMSCKTSGYSFSSYWMHWVKQRPGQGLEWIGYINPS TGYTENNQKFKDKVTLTADKSSNTAYMQLNSLTSEDSAVYYCARSGRLYFDVWGA GTTVTVSSGGGGSGGGGSGGGGSGGGGSDIVLTQSPPSLAVSLGQRATISCRASE SIDLYGFTFMHWYQQKPGQPPKILIYRASNLESGIPARFSGSGSRTDFTLTINPVEAD DVATYYCQQTHEDPYTFGGGTKLEIK Linker: Human CD8aSTK spacer: TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDI Transmembrane derived from human common gamma chain: VVISVGSMGLIISLLCVYFWL Endodomain derived from human common gamma chain: ERTMPRIPTLKNLEDLVTEYHGNFSAWSGVSKGLAESLQPDYSERLCLVSEIPPKGG ALGEGPGASPCNQHSPYWAPPCYTLKPET 2A peptide from equine rhinitis A virus polyprotein: QCTNYALLKLAGDVESNPGP Signal sequence derived from mouse kappa VIII: METDTLILWVLLLLVPGSTG scFv aPSA (5D3D11 H/L): QVQLQQSGPELVKPGASVKISCKVSGYAISSSWMNWVKQRPGQGLEWIGRIYPGD GDTKYNGKFKDKATLTVDKSSSTAYMQLSSLTSVDSAVYFCARDGYRYYFDYWGQ GTSVTVSSGGGGSGGGGSGGGGSGGGGSDIVMTQTAPSVFVTPGESVSISCRSS P108038PCT KSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLASGVPDRFSGSGSGTDFTLRISR VEAEDVGVYYCMQHLEYPVTFGAGTKVEIK Linker: Human K spacer: KIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKP Transmembrane derived from human IL-7Rα: PILLTISILSFFSVALLVILACVLW Endodomain derived from human IL-7Rα: KKRIKPIVWPSLPDHKKTLEHLCKKPRKNLNVSFNPESFLDCQIHRVDDIQARDEVEG FLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACD APILSSSRSLDCRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQ PILTSLGSNQEEAYVTMSSFYQNQ VECTOR The present invention also provides a vector, or kit of vectors, which ses one or more nucleic acid sequence(s) encoding a one or more CCR(s) according to the first aspect of the invention and optionally one or more CAR(s). Such a vector may be used to uce the nucleic acid sequence(s) into a host cell so that it expresses a CCR according to the first aspect of the invention.
The vector may, for example, be a plasmid or a viral vector, such as a retroviral vector or a lentiviral vector, or a transposon based vector or synthetic mRNA.
The vector may be capable of ecting or transducing a T cell or a NK cell.
The present invention provides a cell which comprises one or more CCR(s) of the invention and optionally one of more CAR(s).
The cell may comprise a c acid or a vector of the present invention.
The cell may be a cytolytic immune cell such as a T cell or an NK cell.
P108038PCT T cells or T lymphocytes are a type of lymphocyte that play a central role in cellmediated immunity. They can be distinguished from other lymphocytes, such as B cells and natural killer cells (NK cells), by the presence of a T-cell or (TCR) on the cell surface. There are various types of T cell, as summarised below.
Helper T helper cells (TH cells) assist other white blood cells in immunologic processes, including maturation of B cells into plasma cells and memory B cells, and activation of cytotoxic T cells and macrophages. TH cells s CD4 on their surface. TH cells become activated when they are ted with peptide antigens by MHC class II molecules on the surface of antigen ting cells (APCs). These cells can entiate into one of l subtypes, including TH1, TH2, TH3, TH17, Th9, or TFH, which secrete different cytokines to facilitate different types of immune responses.
Cytolytic T cells (TC cells, or CTLs) destroy virally infected cells and tumor cells, and are also implicated in transplant rejection. CTLs express the CD8 at their surface.
These cells recognize their targets by binding to antigen associated with MHC class I, which is present on the surface of all nucleated cells. Through IL-10, adenosine and other molecules secreted by regulatory T cells, the CD8+ cells can be inactivated to an c state, which prevent autoimmune diseases such as experimental autoimmune encephalomyelitis.
Memory T cells are a subset of antigen-specific T cells that persist long-term after an infection has resolved. They quickly expand to large numbers of effector T cells upon osure to their cognate n, thus providing the immune system with "memory" against past infections. Memory T cells comprise three subtypes: central memory T cells (TCM cells) and two types of or memory T cells (TEM cells and TEMRA cells). Memory cells may be either CD4+ or CD8+. Memory T cells typically express the cell surface protein CD45RO.
Regulatory T cells (Treg , ly known as suppressor T cells, are crucial for the maintenance of immunological tolerance. Their major role is to shut down T cellmediated immunity toward the end of an immune reaction and to suppress autoreactive T cells that escaped the process of negative selection in the thymus.
Two major classes of CD4+ Treg cells have been described — naturally occurring Treg cells and adaptive Treg cells.
P108038PCT Naturally occurring Treg cells (also known as CD4+CD25+FoxP3+ Treg cells) arise in the thymus and have been linked to interactions between developing T cells with both myeloid (CD11c+) and plasmacytoid (CD123+) dendritic cells that have been ted with TSLP. Naturally occurring Treg cells can be distinguished from other T cells by the presence of an intracellular molecule called FoxP3. Mutations of the FOXP3 gene can t regulatory T cell development, causing the fatal autoimmune disease IPEX.
Adaptive Treg cells (also known as Tr1 cells or Th3 cells) may originate during a normal immune response.
The cell may be a Natural Killer cell (or NK cell). NK cells form part of the innate immune . NK cells provide rapid ses to innate signals from virally infected cells in an MHC independent manner NK cells (belonging to the group of innate lymphoid cells) are defined as large granular lymphocytes (LGL) and constitute the third kind of cells differentiated from the common lymphoid progenitor generating B and T lymphocytes. NK cells are known to differentiate and mature in the bone marrow, lymph node, spleen, s and thymus where they then enter into the circulation.
The CCR-expressing cells of the invention may be any of the cell types mentioned above.
T or NK cells ing to the first aspect of the invention may either be created ex vivo either from a patient’s own peripheral blood (1st , or in the setting of a haematopoietic stem cell transplant from donor peripheral blood (2nd party), or peripheral blood from an unconnected donor (3rd party).
Alternatively, T or NK cells according to the first aspect of the invention may be derived from ex vivo differentiation of inducible itor cells or embryonic progenitor cells to T or NK cells. Alternatively, an immortalized T-cell line which retains its lytic function and could act as a therapeutic may be used.
In all these embodiments, CCR-expressing cells are generated by introducing DNA or RNA coding for the or each CCR(s) by one of many means including transduction with a viral , transfection with DNA or RNA.
P108038PCT The cell of the invention may be an ex vivo T or NK cell from a subject. The T or NK cell may be from a eral blood mononuclear cell (PBMC) sample. T or NK cells may be ted and/or expanded prior to being transduced with nucleic acid encoding the molecules providing the CCR according to the first aspect of the ion, for example by treatment with an anti-CD3 monoclonal antibody.
The T or NK cell of the invention may be made by: (i) isolation of a T or NK cell-containing sample from a subject or other sources listed above; and (ii) transduction or transfection of the T or NK cells with one or more a nucleic acid sequence(s) encoding a CCR.
The T or NK cells may then by purified, for example, selected on the basis of expression of the antigen-binding domain of the antigen-binding polypeptide.
PHARMACEUTICAL COMPOSITION The present invention also relates to a pharmaceutical composition containing a plurality of cells according to the invention.
The pharmaceutical composition may additionally comprise a ceutically acceptable carrier, diluent or excipient. The pharmaceutical ition may optionally comprise one or more further pharmaceutically active polypeptides and/or compounds. Such a formulation may, for example, be in a form suitable for intravenous infusion.
METHOD OF TREATMENT The present ion provides a method for treating and/or preventing a disease which comprises the step of administering the cells of the present invention (for example in a pharmaceutical composition as described above) to a subject.
A method for treating a e relates to the eutic use of the cells of the t invention. Herein the cells may be administered to a t having an existing disease or condition in order to lessen, reduce or improve at least one symptom associated with the disease and/or to slow down, reduce or block the progression of the disease.
P108038PCT The method for preventing a disease relates to the prophylactic use of the cells of the present invention. Herein such cells may be administered to a subject who has not yet contracted the disease and/or who is not showing any symptoms of the disease to prevent or impair the cause of the disease or to reduce or prevent development of at least one symptom associated with the disease. The subject may have a predisposition for, or be thought to be at risk of developing, the disease.
The method may involve the steps of: (i) isolating a T or NK cell-containing sample; (ii) transducing or transfecting such cells with a nucleic acid sequence or vector provided by the present invention; (iii) stering the cells from (ii) to a subject.
The T or NK cell-containing sample may be ed from a subject or from other sources, for example as bed above. The T or NK cells may be ed from a subject’s own peripheral blood (1st , or in the setting of a haematopoietic stem cell transplant from donor peripheral blood (2nd party), or eral blood from an unconnected donor (3rd party).
The present invention provides a CCR-expressing cell of the t invention for use in treating and/or preventing a disease.
The invention also relates to the use of a CCR-expressing cell of the present invention in the manufacture of a medicament for the treatment and/or prevention of a e.
The disease to be treated and/or prevented by the methods of the present invention may be a ous disease, such as bladder cancer, breast cancer, colon cancer, endometrial cancer, kidney cancer (renal cell), leukaemia, lung cancer, melanoma, non-Hodgkin lymphoma, pancreatic cancer, prostate cancer and thyroid .
Where the ligand recognised by the CCR is PSA, the cancer may be prostate cancer.
The cells of the present invention may be capable of killing target cells, such as cancer cells. The target cell may be terised by the presence of a tumour secreted ligand or chemokine ligand in the vicinity of the target cell. The target cell may be P108038PCT characterised by the presence of a e ligand together with the sion of a tumour-associated antigen (TAA) at the target cell surface.
The cells and pharmaceutical compositions of present ion may be for use in the ent and/or prevention of the diseases described above.
The cells and ceutical compositions of present invention may be for use in any of the methods described above.
CHIMERIC TRANSMEMBRANE PROTEIN The present invention also provides a chimeric transmembrane n comprising a dimerization domain; and a cytokine receptor endodomain.
Dimerisation may occur spontaneously, in which case the chimeric transmembrane protein will be constitutively . Alternatively, dimerization may occur only in the presence of a al inducer of dimerization (CID) in which case the transmembrane protein only causes cytokine-type signalling in the presence of the CID.
Suitable dimerization domains and CIDs are described in WO2015/150771, the contents of which are hereby incorporated by reference.
For example, one dimerization domain may comprise the rapamycin binding domain of FK-binding protein 12 (FKBP12), the other may comprise the FKBP12-Rapamycin Binding (FRB) domain of mTOR; and the CID may be rapamycin or a derivative thereof.
One zation domain may comprise the FK506 (Tacrolimus) binding domain of FK- binding protein 12 (FKBP12) and the other dimerization domain may comprise the cyclosporin binding domain of cylcophilin A; and the CID may be an FK506/cyclosporin fusion or a derivative thereof.
One dimerization domain may comprise an oestrogen-binding domain (EBD) and the other dimerization domain may comprise a streptavidin g domain; and the CID may be an estrone/biotin fusion n or a derivative thereof.
One dimerization domain may comprise a glucocorticoid-binding domain (GBD) and the other dimerization domain may comprise a dihydrofolate reductase (DHFR) binding P108038PCT ; and the CID may be a dexamethasone/methotrexate fusion protein or a derivative thereof.
One dimerization domain may se an O6-alkylguanine-DNA alkyltransferase (AGT) binding domain and the other dimerization domain may comprise a dihydrofolate reductase (DHFR) binding domain; and the CID may be an O6-benzylguanine derivative/methotrexate fusion protein or a derivative thereof.
One dimerization domain may comprise a retinoic acid receptor domain and the other dimerization domain may comprise an ecodysone receptor domain; and the CID may be RSL1 or a derivative thereof.
Where the dimerization domain spontaneously heterodimerizes, it may be based on the dimerization domain of an antibody. In particular it may comprise the dimerization portion of a heavy chain constant domain (CH) and a light chain constant domain (CL).
The "dimerization portion" of a constant domain is the part of the sequence which forms the inter-chain disulphide bond.
The chimeric ne receptor may comprise the Fab portion of an antibody as exodomain, for example as illustrated schematically in Figure 5..
The ic transmembrane n may comprise two polypeptides: (i) a first polypeptide which ses: (a) a first dimerisation domain; and (b) a first chain of the cytokine receptor endodomain; and (ii) a second polypeptide which comprises: (a) a second dimerization domain, which dimerises with the first dimerization domain; (b) a second chain of the cytokine-receptor endodomain.
The sections above ng the cytokine receptor endodomain of the chimeric cytokine receptor also apply to the ic transmembrane protein of the present invention.
The sections above relating to c acids, vectors, kits, cells, pharmaceutical compositions and s also apply to the chimeric transmembrane protein of the present invention.
P108038PCT The invention will now be further described by way of Examples, which are meant to serve to assist one of ordinary skill in the art in carrying out the invention and are not intended in any way to limit the scope of the invention.
EXAMPLES Example 1 – In vitro testing T-cells are transduced with either a PSMA-specific CAR or transduced with a uct which co-expresses a PSMA-specific CAR with a PSA-specific CCR. T-cells are co- cultured with PSMA expressing target cells which secrete or do not secrete PSA. This co-culture is conducted in the ce or absence of exogenous IL2. This ture is conducted at different effector to target ratios. This co-culture is repeated serially with T-cells challenged with repeated target cells. Proliferation of T-cells and killing of target cells is determined. In this way, the contribution to proliferation and al of T-cells the CCR makes can be measured. Further, the ability contribution to repeated rechallenge the ability of serial Example 2 - In vivo testing NSG mice are engrafted with a human prostate cancer cell line which expresses PSMA and secretes PSA and which expresses firefly rase. T-cells are transduced with either a PSMA-specific CAR or transduced with a construct which co-expresses the PSMA-specific CAR with a PSA-specific CCR. T-cells are administered to the mice.
The tumour burden can be serially measured using bioluminescent imaging and the response to CAR s evaluated. Mice within each cohort can be sacrificed at different time-points and tumour burden directly measured by copic measurements and by histochemistry. Further, engraftment / expansion of T- cells at the tumour bed or within lymphoid s such as lymph nodes, spleen and bone-marrow measured by flow cytometry of said tissues.
Example 3 – Creation of and testing a tutively active cytokine-signalling molecule A constitutively active cytokine-signalling chimeric transmembrane protein was produced by linking cytokine receptor endodomains to a "Fab" type exodomain (Figure ). This ure uses the natural dimerization components of antibodies, namely the dimerization domain from the heavy and light chain constant regions. The ic transmembrane protein has two chains; a first polypeptide which comprises the antibody light κ chain and the IL2 receptor common γ chain as endodomain; and a second polypeptide which comprises the antibody heavy chain CH1 and an endodomain which comprises either: the IL2 receptor β chain (giving a constitutively active IL2-signalling molecule); or the IL7 receptor g a constitutively active IL7- ling le). The constitutively active ne-signalling chimeric transmembrane proteins tested in this study included the scFv heavy and light chain variable s. These domains are not needed for dimerization to occur. The signal is independent of antigen binding and the structure could equally be "headless" (as shown in Figure 5) or comprise another entity such as a n tag.
Nucleic acid sequences encoding these two polypeptides were cloned in frame separated by a 2A-peptide encoding sequence.
CTLL-2 (ATCC® TIB-214™) are murine cytotoxic T lymphocyte cells which are dependent upon IL-2 for growth. In the absence of IL-2 the cells undergo apoptosis.
CTLL-2 cells were transduced with a vector expressing the chimeric protein comprising an IL2-receptor endodomain L2endo) or a vector expressing the chimeric protein comprising an IL7 receptor endodomain (Fab_IL7endo) or left untransduced (WT). As a positive control, cells of all three types were co-cultured with 100 U/ml murine IL2.
Cell proliferation was ed after 3 and 7 days of e and the results are shown in Figure 6.
Untransduced CTLL2 cells, together with CTLL2 cells transduced with either construct (Fab_IL2endo or Fab_IL7endo) proliferated in the presence of 100U/mL murine IL2 (Figure 6, left-hand panel). However, in the absence of exogenously added IL2, only cells transduced with the construct having an IL2R endodomain (Fab_IL2endo) survived and proliferated. This shows that the chimeric transmembrane receptor provides the CTLL2 cells with the necessary IL2 signal.
Example 4 – Generation and g of a chimeric ne receptor against PSA A panel of chimeric cytokine receptors targeting PSA was developed using scFvs derived from two antibodies which bind to different PSA epitopes: 5D5A5 and 5D3D11.
The crystal structure of PSA has been obtained in a ch complex with these two (Stura et al (2011) as above).
Schematic diagrams illustrating some of the panel of CCRs is illustrated in Figure 7.
The panel included the following constructs: P108038PCT A5-CD8stk-IL2Rg_D11-Hinge-IL2Rb: A CCR with an IL -2R endodomain having A5 on the chain with common γ chain and D11 on the chain with the IL2R β chain; D11-CD8stk- IL2Rg_A5-Hinge-IL2Rb: A CCR with an IL-2R endodomain having D11 on the chain with common γ chain and A5 on the chain with IL2R β chain; D11-CD8stk- RL _A5-Hinge -IL2Rb: A negative control uct which is equivalent D11-CD8stk- IL2Rg_A5-Hinge-IL2Rb, but in which the IL2Rγ chain is replaced by a rigid linker; D11-CD8stk- IL2Rg_A5-Hinge-IL7Ra: A CCR with an IL-7R endodomain having D11 on the chain with common γ chain and A5 on the chain with IL7R α chain; and D11-CD8stk- RL _A5-Hinge –IL7Ra: A negative control construct which is equivalent D11-CD8stk- IL2Rg_A5-Hinge-IL7Ra, but in which the IL2Rγ chain is replaced by a rigid linker; CTLL2 cells were transduced with vectors sing these constructs. Cells were cultured in the presence or absence of IL2 (the presence of IL2 acting as a positive control) and the presence or absence of 5ng/mL or 5μg/mL PSA. CTLL2 cell proliferation was assessed after 3 and 7 days and the results are shown in Figure 8.
CTLL2 cells expressing a CCR with an IL7 endodomain did not support CTLL2 cell al and proliferation (Figure 8, last two ). The presence of murine IL-2 in these cells supported CTLL2 cell growth and proliferation at day 3, but by day 7 the majority of cells had undergone apoptosis.
The anti-PSA chimeric cytokine receptors with an IL2R endodomain supported CTLL2 cell eration in the absence of IL2 and the presence of PSA at both 5ng/ml and 5μg/ml (Figure 8, first panel), with 5μg/ml givinggreater survival and proliferation, particularly at day 7.
Both the SA chimeric cytokine receptors with an IL2R endodomain, i.e. A5- CD8stk-IL2Rg_D11-Hinge-IL2Rb and D11-CD8stk- IL2Rg_A5-Hinge-IL2Rb, ting that the relative positioning of the two PSA-binding domains: 5D5A5 and 5D3D11, is not important for function.
Substitution of the common γ chain with a rigid linker abolished the capacity of the CCR to t CTLL2 cell survival and proliferation (Figure 8, third panel).
P108038PCT As another read-out for IL2 signalling, the phosphorylation of Y694 of STAT5 was investigated using phosphoflow.
CTLL2 cells were either untransduced (WT); transduced with a PSA CCR constructs having an IL2R endodomain (D11-CD8STK-IL2Rg_A5-Hinge-IL2Rb); or transduced with an equivalent negative control construct in which the IL2Rγ chain is replaced with a rigid linker (D11-CD8STK-RL_A5-Hinge-IL2Rb). The cells were incubated overnight in the absence of exogenously added IL-2. The following day, the cells were incubated with either Pervanadate at 500μM (a ve control which inhibits phosphatase and will lead to STAT5 phoshorylation) or 500ng/mL PSA for 1 or 4 hours. After incubation the cells were fixed, permeabilised and analysed by flow cytometry.
The results are shown in Figure 9. In the cells expressing the PSA CCR, the presence of PSA lead to increasing STAT5 phosphorylation with time (Figure 9, central panel).
No such increase in orylation was seen with untransduced CTLL2 cells, or with CTLL2 cells transduced with an equivalent construct in which the IL2Rγ chain is replaced with a rigid linker (Figure 9, right hand panel).
These results are consistent with the CTLL2 survival/proliferation data shown in Figure 8 and demonstrate that a chimeric cytokine receptor against a soluble ligand (here, PSA) can be used to trigger cytokine signalling in a T-cell.
All publications mentioned in the above specification are herein incorporated by reference. Various modifications and ions of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been bed in connection with specific red ments, it should be understood that the ion as claimed should not be unduly limited to such specific embodiments.
Indeed, various cations of the bed modes for carrying out the invention which are obvious to those d in molecular biology or related fields are intended to be within the scope of the following claims.
Claims (21)
1. A chimeric transmembrane protein which comprises two polypeptides: (i) a first polypeptide which comprises: (a) a heavy chain constant domain (CH) (b) a first chain of a type 1 cytokine receptor main; and (ii) a second polypeptide which comprises: (a) a light chain constant domain (CL) (b) a second chain of the type 1 cytokine-receptor endodomain.
2. A chimeric embrane protein according to claim 1, wherein the cytokine receptor endodomain comprises: (i) IL-2 or β-chain endodomain (ii) IL-7 receptor α-chain main; (iii) IL-15 receptor α-chain endodomain; or (iv) common γ-chain receptor endodomain.
3. A chimeric transmembrane protein according to claim 1, n the first polypeptide comprises a heavy chain variable domain (VH) and a heavy chain constant domain (CH); and the second polypeptide comprises a light chain variable domain (VL) and a light chain constant domain (CL).
4. A chimeric transmembrane protein ing to claim 3 which comprises a Fab exodomain.
5. An ex vivo cytolytic immune cell which comprises a chimeric transmembrane protein according to any one of claims 1 to 4.
6. A cytolytic immune cell according to claim 5 which also comprises a chimeric antigen receptor.
7. A cytolytic immune cell according to claim 6 wherein the ic antigen or binds a -associated cell surface antigen.
8. A nucleic acid sequence encoding a chimeric transmembrane protein according to any one of claims 1 to 4.
9. A nucleic acid construct which comprises a first nucleic acid sequence encoding a first polypeptide as defined in claim 1 and a second nucleic acid ce encoding a second polypeptide as defined in claim 1, the nucleic acid construct having the structure: CH-TM1-endo1-coexpr-CL-TM2-endo2 in which CH is a nucleic acid sequence encoding the heavy chain constant domain of the first polypeptide; TM1 is a nucleic acid sequence encoding the transmembrane domain of the first polypeptide; endo 1 is a nucleic acid sequence encoding the endodomain of the first polypeptide; coexpr is a nucleic acid sequence enabling co-expression of both first and second ptides CL is a nucleic acid sequence encoding the light chain constant domain of the second polypeptide; TM2 is a nucleic acid sequence encoding the transmembrane domain of the second polypeptide; endo 2 is a nucleic acid sequence encoding the endodomain of the second polypeptide.
10. A nucleic acid construct according to claim 9, which also encodes a chimeric antigen receptor (CAR).
11. A nucleic acid construct according to claim 9 or claim 10 wherein coexpr encodes a sequence comprising a leaving peptide
12. A nucleic acid according to any one of claims 9 to 11 wherein alternative codons are used in regions of sequence encoding the same or similar amino acid sequences in order to avoid homologous recombination.
13. A vector comprising a nucleic acid construct according to any one of claims 9 to 12.
14. A vector according to claim 13 which is a retroviral , a lentiviral vector or a transposon.
15. A kit which comprises: i) a vector sing a c acid sequence encoding a first polypeptide as defined in claim 1; and ii) a vector comprising a c acid sequence encoding a second polypeptide as defined in claim 1.
16. A kit ing to claim 15 which also comprises a vector comprising a nucleic acid sequence encoding a chimeric antigen receptor.
17. A kit which comprises: i) a vector comprising a nucleic acid sequence encoding a ic transmembrane protein as defined in any one of claims 1 to 4; and ii) a vector comprising a nucleic acid sequence encoding a chimeric antigen receptor.
18. A method for making a cell according to any one of claims 5 to 7, which comprises the step of ucing: a nucleic acid sequence according to claim 8; a nucleic acid construct according to any one of claims 9 to 12; a vector according to claim 13 or 14; or a kit of vectors ing to any one of claims 15 to 17, into a cell isolated from a subject.
19. A pharmaceutical composition comprising a plurality of cytolytic immune cells ing to any one of claims 5 to 7.
20. A pharmaceutical composition according to claim 19 for use in treating and/or preventing a disease.
21. The use of a cytolytic immune cell according to any one of claims 5 to 7 in the manufacture of a medicament for treating and/or preventing a disease. u W38 ”33% smegmaéc mmfiowfi mmggmgfl mmmgmmmmmu $8CE Em “$5 £me .h “mum £me Em Eu. :2 38 Em E m ”:3“ $3 ammo mmmmo Egg Em £8 $8 Em E. K“mgagoa K7“ $8 mag Emma wmmo ”mu: £me ammmfiam mwfigogmom WEQE ”mega am méa mom Em mmmfigfifl Em £me ammo “E. $3 ._. mama $me £me mmfigmmom "mung Emma P #me m u: g7“ Em £30 “mmmmu mmmfiomg E. M7“ Em $0335 mmg mmmwmaxm flag wag E was $393 in 538% 33 Em .w. gm SUBSTITUTE SHEET (RULE 26) WO 29512 FEG. 2 SUBSTITUTE SHEET (RULE 26) Enhancer LgafidA+ UgandA BinderA 9mmm §"§ f f ‘Cmmm lL-HQamha I 3 3 § § ganwnachan Chain . Sanamng E3EC3.i3 SUBSTITUTE SHEET (RULE 26) 1 PSMA , @591) a AnflPSA(EDSA5) Ligand/55+ Target cell membrane Ssiubie E:and minced agegation of ihe phosphatase CAR ffffffffffffff Signaiiang Signafiiing FEG. 3 (Cantimed) SUBSTITUTE SHEET (RULE 26) WWEWW WWWEW WEE WW0 WWWWWuWW WWW Eumgw WEEEE <3OW EWWW WOW WWWWWEWW WWWWW $5.;me «mm 8 EEEQQ WWWEWWW umNWWmWWEWmW WW5: WWWWW WWWEWWWWWE W WE. .WWWWWQWWWWW mEEmm Wag EmWE EEW EWWW mag Em WWEWWW EESWEEEWE EEEEWWWEW EWWEEEWWW EOE WW mWWWWWWmmWWW wcoWWmEWoW EWWEWQ E233 Emu EEWME WWWWW EWWWW.oWW. WW0 mE EWWWWWWWEW mEoWWoWWWm WWWWW WWWEWW EWW WO WWW WEWWWWWWW . WWWEWW SUBSTITUTE SHEET (RULE 26) Ab ngin i: chain Ab Heavy chain (Ci-ii) Hinge spacer Hinge spacer ii_2 recepier ELZrecepierifi cernrnenycnain chain or ii] receptor (1 chain dimerizaiien signei PEG. 5 SUBSTITUTE SHEET (RULE 26) . m>< ...................................... gram 99chng . . 800$ magma? $on Q F?» mm»owcmfimmmw 33:33 3M; $953 Q mflww NEG “3.5 .MVE {as an? Lap... $3334 was”: JEEEDQE ................................................................................................................... $40 ngogmw WQOQQOV Wgeogm Q 93393 9mg SUBSTITUTE SHEET (RULE 26) WO 29512 FEG. 7 SUBSTITUTE SHEET (RULE 26) NJWQZ mgmggtaoaw 02 nan gm; >.Av. msmwfi>.fi$. QmNmeQg+m.$w. «wngtmgmw>>.fiw mmwgfimmgwwm> “H w («Am oEimEmQ gun03 SUBSTITUTE SHEET (RULE 26)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1514875.2A GB201514875D0 (en) | 2015-08-20 | 2015-08-20 | Receptor |
GB1514875.2 | 2015-08-20 | ||
PCT/GB2016/052564 WO2017029512A1 (en) | 2015-08-20 | 2016-08-19 | Chimeric cytokine receptor |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ739942A NZ739942A (en) | 2022-03-25 |
NZ739942B2 true NZ739942B2 (en) | 2022-06-28 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11479613B2 (en) | Methods for treating cancer or modulating T cells or NK cells in a subject by administering cells comprising chimeric transmembrane proteins | |
US20220275052A1 (en) | Receptor | |
US20220289820A1 (en) | Chimeric cytokine receptor | |
US20200239545A1 (en) | Receptor | |
US20240075066A1 (en) | Cell | |
NZ739942B2 (en) | Chimeric cytokine receptor | |
WO2023073352A1 (en) | Chimeric cytokine receptor | |
KR20240093884A (en) | Chimeric cytokine receptor |